CDMRP - Prostate Cancer Research Program (PCRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Prostate Cancer Research Program (PCRP), administered by the Congressionally Directed Medical Research Programs (CDMRP), is expected to release multiple funding opportunities supporting innovative, high-impact prostate cancer research with clinical relevance. The program is focused on eliminating death and suffering from prostate cancer through new therapies, improved clinical care, survivorship research, and better understanding of disease progression.

This is currently a pre-announcement. Funding opportunity announcements will be posted later on Grants.gov and will include official pre-application and application deadlines. At this time, the application deadline is not specified in the solicitation.

How much funding would I receive?

Funding amounts depend on the award mechanism.

• Data Science Award

  • Maximum allowable funding is $1.4 million for total costs

  • Maximum period of performance is 3 years

• Early Investigator Research Award

  • Maximum allowable funding is $630,000 for total costs

  • Maximum period of performance is 3 years

• Idea Development Award

  • Established Investigator Option:

    • Maximum allowable funding is $1.7M for total costs

    • Maximum period of performance is 3 years

  • New Investigator Option:

    • Maximum allowable funding is $2.1M for total costs

    • Maximum period of performance is 4 years

• Physician Research Award

  • Maximum allowable funding is $1.1M for total costs

  • Maximum period of performance is 4 years

The solicitation states that total costs include direct and indirect costs.

What could I use the funding for?

The allowable use of funds depends on the award mechanism.

Data Science Award supports research that develops or uses quantitative and analytical approaches, processes, and/or systems to obtain knowledge and insight from large and/or complex sets of prostate cancer data in areas including:

• Analysis of clinically annotated datasets

• Analysis of “-omics” data

• Artificial intelligence and machine learning

• Bioinformatics

• Computational biology

• Digital pathology

• Epidemiology

• Medical imaging

Early Investigator Research Award supports prostate cancer research conducted by early-stage investigators under mentorship from experienced researchers.

Idea Development Award supports innovative, high-risk and high-gain approaches to prostate cancer research.

Physician Research Award supports mentored research experiences for physicians pursuing careers in prostate cancer research and clinical practice.

Several mechanisms allow clinical research and correlative studies associated with ongoing or completed clinical trials, but clinical trials themselves are not allowed under these awards.

Are there any additional benefits I would receive?

Potential additional benefits include:

• Access to CDMRP-administered funding programs with national visibility

• Support for researcher career development and mentorship under the Early Investigator Research Award and Physician Research Award

• Flexibility for multidisciplinary and multi-institutional collaboration under certain award mechanisms

• Opportunity to pursue high-risk, high-gain research concepts through the Idea Development Award

The solicitation also encourages, but does not require:

• Preliminary data for several award mechanisms

• Multidisciplinary projects

• Multi-institutional projects

What is the timeline to apply and when would I receive funding?

This notice is a pre-announcement only.

The solicitation states that:

• Funding opportunity announcements will be posted later on Grants.gov

• Once released, the funding opportunity announcements will include pre-application and application deadlines

• The PCRP requires submission of a letter of intent prior to full application submission

• Before full application submission, the CDMRP requires submission of a pre-application through eBRAP prior to the pre-application deadline

The application deadline is not specified in the solicitation.

The timing for award decisions or funding distribution is not specified in the solicitation.

Where does this funding come from?

The funding comes from the FY26 Defense Appropriations Act and is administered through:

• Defense Health Agency Research and Development (DHA R&D)

• Medical Research and Development Command (MRDC)

• Congressionally Directed Medical Research Programs (CDMRP)

The funding opportunity is part of the FY26 Prostate Cancer Research Program (PCRP).

Who is eligible to apply?

Eligibility depends on the award mechanism.

Data Science Award

• Independent investigators at all levels

Early Investigator Research Award

• Early-career investigators possessing a doctoral degree, or equivalent, with fewer than 3 years of postdoctoral research experience at the application submission deadline, excluding clinical residency or clinical fellowship training

Idea Development Award
Established Investigators:

• Independent investigators at all levels

New Investigators:

• Independent investigators that:

  • Have not previously received a PCRP Idea Development Award and/or Health Disparity Research Award

  • Either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of terminal degree, excluding residency or family medical leave

Physician Research Award

• Early-career clinician investigators that are either:

  • In the last year of an accredited medical residency or medical fellowship program

  • Within 5 years of initiating a faculty appointment, including instructor positions or equivalent

Additional personnel requirements apply for mentored mechanisms.

What companies and projects are likely to win?

Projects are likely to be competitive if they:

• Address one or more of the PCRP’s overarching challenges

• Demonstrate clinical relevance and potential impact

• Propose innovative approaches to prostate cancer research

• Focus on improving outcomes for patients with lethal prostate cancer

• Advance survivorship, wellness, or clinical care

• Improve understanding of progression to lethal prostate cancer

The solicitation specifically emphasizes:

• Innovation and impact equally under the Idea Development Award

• High-risk and high-gain approaches

• Quantitative and analytical methods for large and complex prostate cancer datasets under the Data Science Award

Are there any restrictions I should know about?

Key restrictions include:

• Applications cannot support clinical trials under all listed award mechanisms

• Data Science Award applications cannot support prospective recruitment of human subjects

• Several awards require submission of a letter of intent prior to full application submission

• Full applications must conform to the final funding opportunity announcements available on Grants.gov

• Certain mechanisms require mentorship and researcher development plans

• Physician Research Award applications strongly encourage protection of at least 20% of the PI’s time for prostate cancer research

The solicitation states that this announcement is only a pre-announcement and should not be construed as an obligation or promise by the government.

How long will it take me to prepare an application?

The solicitation does not specify expected preparation time.

However, applicants should anticipate preparing:

• A pre-application through eBRAP

• A letter of intent

• A full application package

• Research development plans for mentored mechanisms

• Supporting documentation related to eligibility, mentorship, and project scope

Because official funding opportunity announcements and deadlines have not yet been released, applicants may benefit from beginning project planning early.

How can BW&CO help?

BW&CO can help companies and research teams:

• Evaluate which FY26 PCRP mechanism best aligns with their technology or research program

• Position projects around the program’s stated overarching challenges

• Develop commercialization and impact narratives

• Coordinate scientific, clinical, and subcontractor partners

• Manage proposal development, writing, compliance, and submission

• Prepare pre-applications, letters of intent, and full proposals

Additional Resources

Review solicitation here.

CDMRP - Neurofibromatosis Research Program (NFRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Neurofibromatosis Research Program (NFRP), administered by the Congressionally Directed Medical Research Programs (CDMRP), is expected to fund multiple award mechanisms supporting innovative, high-impact neurofibromatosis (NF) and schwannomatosis research. The program is specifically focused on improving understanding, diagnosis, treatment and quality of life outcomes for people affected by NF and schwannomatosis, including Service Members, Veterans and their families.

Pre-Application due August 31st

Full Application due September 14th

How much funding would I receive?

The FY26 NFRP includes multiple anticipated award mechanisms with varying funding levels:

• Exploration-Hypothesis Development Award

  • Maximum allowable funding: $160,000 total costs

  • Maximum performance period: 2 years

• Investigator-Initiated Research Award

  • Maximum allowable funding: $525,000 total costs

  • Maximum performance period: 3 years

  • Applications using the Qualified Collaborator or NF Open Science Initiative options may request up to $575,000 total costs

• Neurofibromatosis Research Academy – Leadership Award

  • Maximum allowable funding: $2.4 million total costs

  • Maximum performance period: 4 years

• Neurofibromatosis Research Academy – Scholar Award

  • Maximum allowable funding: $1.2 million total costs

  • Maximum performance period: 4 years

• Synergistic Idea Award

  • Maximum allowable funding: $3.2 million total costs

  • Maximum performance period: 3 years

Total costs include both direct and indirect costs.

What could I use the funding for?

Funding is intended to support innovative and impactful neurofibromatosis and schwannomatosis research projects.

Potential project areas include:

• Schwannomatosis and NF2-related research

• Biomarker and endpoint validation

• Data science applications

• Pain and cognitive manifestation research

• Sleep-related NF research

• Genomics, epigenetics and systems biology

• Drug discovery and target identification

• Preclinical efficacy studies

• Nutritional and environmental modifiers of NF

• Health services research

Specific award mechanisms also support:

• Early-stage exploratory concepts

• Multi-investigator collaborative projects

• Early-career investigator development

• Multi-institutional mentoring academies

• Pilot research projects within academy structures

Clinical trials are not allowed under the listed award mechanisms.

Are there any additional benefits I would receive?

Depending on the award mechanism, applicants may receive additional benefits such as:

• Access to collaborative research partnerships

• Participation in the NF Open Science Initiative

• Intensive mentoring and career development

• National networking opportunities

• Participation in a virtual NF research academy

• Access to NF Consumer Consultant Panels

• Multi-institutional collaboration opportunities

The Neurofibromatosis Research Academy mechanisms are specifically designed to support mentorship, networking and long-term investigator development in the NF field.

What is the timeline to apply and when would I receive funding?

Pre-Application due August 31st

Full Application due September 14th

The program requires submission of a pre-application through eBRAP prior to full application submission.

Periods of performance vary by award mechanism:

• 2 years for Exploration-Hypothesis Development Awards

• 3 years for Investigator-Initiated Research Awards

• 4 years for Academy Leadership Awards

• 4 years for Academy Scholar Awards

• 3 years for Synergistic Idea Awards

The solicitation does not specify anticipated award start dates or funding disbursement timelines.

Where does this funding come from?

Funding comes from the FY26 Defense Appropriations Act through the Department of Defense Congressionally Directed Medical Research Programs (CDMRP), managed within the Defense Health Agency Research and Development – Medical Research and Development Command (DHA R&D-MRDC).

Who is eligible to apply?

Eligibility depends on the award mechanism.

Exploration-Hypothesis Development Award:

• Investigators at all career levels

• Includes postdoctoral fellows or equivalent

Investigator-Initiated Research Award:

• Investigators at or above the level of Assistant Professor or equivalent

• Must commit a minimum of 10% effort throughout the award

Neurofibromatosis Research Academy – Leadership Award:

• Academy Director must be an established NF investigator at or above Associate Professor or equivalent

• Academy Deputy Director must also be at or above Associate Professor level and affiliated with a different institution

Neurofibromatosis Research Academy – Scholar Award:

• Scholars must be early-career investigators within 10 years of terminal degree or clinical fellowship

• Requires an eligible Career Guide who is an established NF investigator

Synergistic Idea Award:

• Investigators at or above the level of Assistant Professor or equivalent

Additional eligibility requirements may be included in the final funding opportunity announcements.

What companies and projects are likely to win?

The NFRP is seeking projects that are:

• Innovative and high-impact

• Clinically relevant

• Focused on improving patient outcomes

• Addressing one or more stated Areas of Emphasis

• Advancing understanding, diagnosis or treatment of NF and schwannomatosis

Competitive applications are likely to include:

• Strong scientific rationale

• Significant translational potential

• Collaborative or multidisciplinary approaches

• Novel technologies or methodologies

• Preliminary and/or published data where required

Certain award mechanisms specifically encourage:

• High-risk, high-gain concepts

• Multi-investigator collaboration

• Data science approaches

• Open science participation

• Mentorship and workforce development in NF research

The solicitation also emphasizes research that could benefit Service Members, Veterans and the broader public.

Are there any restrictions I should know about?

Yes. Key restrictions include:

• Clinical trials are not allowed under the listed award mechanisms

• Several award mechanisms require preliminary and/or published data

• All applications require a pre-application submission through eBRAP before full application submission

• Multiple award mechanisms require submission of a letter of intent prior to full application submission

• Applications must conform to the final funding opportunity announcements posted on Grants.gov

The pre-announcement states that investigators should not construe the notice as an obligation or promise by the government.

How long will it take me to prepare an application?

Preparation timelines will vary significantly depending on the award mechanism.

Applicants pursuing:

• Multi-institutional collaborations

• Academy proposals

• Large-scale synergistic projects

• Open science options

should expect substantially longer preparation timelines due to coordination requirements, mentoring structures, collaborator commitments and supporting documentation.

Because all applications require pre-applications and several require letters of intent, applicants should begin planning before the official funding opportunity announcements are released.

How can BW&CO help?

BW&CO can support applicants with:

• Opportunity assessment and award mechanism selection

• Research strategy positioning

• Commercialization and impact narrative development

• Proposal writing and editing

• Collaboration structuring

• Project management and submission coordination

• Budget development support

• Grants.gov and eBRAP submission support

• Reviewer-style proposal feedback

Additional Resources

Review solicitation here.

ARPA- E INSPIRING GENERATIONS OF NEW INNOVATORS TO IMPACTTECHNOLOGIES IN ENERGY 2026 (IGNIITE 2026)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The IGNIITE 2026 program from ARPA-E is a high-prestige, early-career funding opportunity designed to support transformational, high-risk energy technologies. It is not founder-friendly in structure (no teams, no co-PIs), but offers meaningful non-dilutive funding and strong ecosystem access.

You must first submit a Concept Paper by 9:30 AM ET, May 29, 2026.

If selected, you may be invited to submit a full application. With only ~$10M total funding and awards capped at $500K, this is a competitive but accessible entry point into ARPA-E for early-career innovators.

How much funding would I receive?

• Individual awards: up to $500,000

• Potential additional funding:

  • Up to $250,000 Director’s Award (at ARPA-E’s discretion)

• Total program funding: approximately $10 million

• Number of awards: Not specified (ARPA-E may issue one, multiple, or no awards)

What could I use the funding for?

Applicants are advised to assess whether their proposed technologies are aligned with the DOE’s current areas of interest. Those areas include, but are not limited to:

• Energy supply chain security (to include critical minerals)

• Advanced nuclear (to include fusion, fission)

• Geothermal

• Grid reliability and security

• American manufacturing competitiveness

Are there any additional benefits I would receive?

Yes—this program includes structured ecosystem access:

• Participation in the IGNIITE Annual Program (two one-week sessions in Washington, D.C.)

• Training (e.g., proposal writing, commercialization, pitching)

• Direct engagement with:

  • ARPA-E Program Directors

  • Investors

  • Federal stakeholders

• Mentorship and networking opportunities

What is the timeline to apply and when would I receive funding?

Key deadlines:

• Concept Paper questions deadline: 5 PM ET, May 19, 2026

• Concept Paper submission deadline: 9:30 AM ET, May 29, 2026

• Invite / Not Invite notifications: 5 PM ET, July 14, 2026

• Full application deadline: Not specified (TBD)

• Selection notifications: September 2026 (anticipated)

• Award start: December 2026 (anticipated)

Period of performance:

• December 2026 – December 2028

Where does this funding come from?

• Advanced Research Projects Agency—Energy (ARPA-E)

• Within the U.S. Department of Energy (DOE)

Authorized under federal statute (America COMPETES Act and subsequent amendments).

Who is eligible to apply?

This program is highly specific and restrictive:

Principal Investigator (PI) requirements

• Must be an early-career researcher

• PhD received within 8 years of the Concept Paper deadline

• Must be:

  • U.S. citizen, permanent resident, or green card applicant

• If at a university:

  • Must be a pre-tenure Assistant/Associate Professor

• Must self-direct the project (no co-PIs allowed)

Eligible organizations

• For-profit companies

• Universities

• Nonprofits

• DOE labs / FFRDCs

Additional constraints:

• Must apply as a standalone applicant (no teams or subrecipients)

• Must be U.S.-based with majority domestic ownership

What companies and projects are likely to win?

Competitive projects will:

• Be transformational (not incremental)

• Have potential to be disruptive in the market

• Demonstrate clear technical risk with high upside

• Include hypothesis-driven R&D with measurable outcomes

ARPA-E prioritizes:

• Novel concepts that could create new technology “learning curves”

• Technologies with clear commercialization potential

• Strong technical justification and feasibility

Projects will be rejected if they:

• Are incremental improvements

• Lack scientific rigor

• Cannot scale or become disruptive

Are there any restrictions I should know about?

Key restrictions include:

• No cost share required

• Must spend at least 5% on Technology Transfer & Outreach (TT&O)

• Work must generally be performed in the U.S.

• Limited or restricted:

  • Foreign participation (requires waiver)

  • Foreign travel

  • Major construction

Other constraints:

• Cannot submit more than one application per PI

• Must comply with strict federal reporting, disclosure, and security requirements

How long will it take me to prepare an application?

Based on requirements:

Concept Paper (required first step)

Includes:

• Technical concept (4 pages)

• Personal qualification summary (2 pages)

• Summary slide

• Letter of support

• Transcript

Full Application (if invited)

Includes:

• 15-page technical volume

• Budget workbook

• Multiple federal forms and disclosures

• Biosketches and support documentation

Estimated effort:

• Concept Paper: 2–4 weeks

• Full Application: 6–10+ weeks

How can BW&CO help?

BW&CO can support you across the full process:

• Positioning your concept as “transformational” (not incremental)

• Translating technical ideas into ARPA-E-aligned narratives

• Structuring your Concept Paper for invite likelihood

• Building a clear commercialization and impact story

• Managing compliance with ARPA-E formatting and submission rules

Additional Resources

Review solicitation here.

Low-Cost Uncrewed Combat Attack System (LUCAS) Component Challenge

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Low-Cost Uncrewed Combat Attack System (LUCAS) Component Challenge is an open, rolling solicitation seeking dual-use technologies that reduce cost and improve performance across LUCAS subsystems. This is not for building a full aircraft—it is strictly for components that can integrate into existing or future LUCAS platforms.

The challenge window is open for one hundred twenty days from posting, with weekly reviews and rapid down-selects anticipated within thirty to forty-five days of submission. Companies that are ready to deliver testable prototypes quickly should apply as early as possible to maximize selection odds.

Deadline is June 24th, 2026.

How much funding would I receive?

Funding typically ranges from $500k - $5m per award.

Desired Solution

The government seeks prototypes and concepts that reduce cost, increase performance, improve manufacturability, and strengthen mission adaptability across the LUCAS family. Components may target aircraft already fielded, upcoming variants, or platform-agnostic interfaces intended for future LUCAS systems.

These technology areas include:

a) Artificial Intelligence (AI): Machine learning, perception, autonomy, and decision aids that enhance mission planning, predictive maintenance, and autonomous performance while reducing operator workload.

b) Mission Command Planner and Executor: Tools that translate commander intent into executable tasking for LUCAS platforms, enabling rapid re-tasking, synchronization, and secure mission execution.

c) Payload – Kinetic and Non-Kinetic: Modular payloads providing offensive, defensive, and sensing effects, emphasizing rapid interchangeability, safe integration, and interoperability across mission profiles.

d) Navigation Systems: Avionics and navigation suites resilient to degraded or GPSdenied environments, leveraging multi-sensor fusion, inertial navigation, and antijam/anti-spoofing technologies.

e) Alternative Energy: Onboard or distributed energy systems that extend endurance, reduce logistics burden, and enable sustained operations, including hybrid, fuel cell, or regenerative power options.

f) Engines: Power and propulsion units focused on reliability, maintainability, and energy efficiency, supporting rapid maintenance and multi-fuel adaptability.

g) Manufacturing Capabilities: Advanced production methods such as additive manufacturing and modular assembly that reduce cost, shorten lead times, and improve supply chain resilience.

h) Test and Evaluation Capabilities: Rapid, repeatable validation tools and instrumentation, including hardware-in-the-loop, automated test frameworks, and performance data analytics.

i) Integration Labs: Physical or virtual environments that accelerate interoperability testing, software-hardware integration, and government-industry co-development using standardized interfaces.

j) One-Way Attack Systems: Affordable, expendable loitering or single-use systems emphasizing safety, accuracy, and low-cost production for tactical effects.

k) Range-Extending Technologies: Communication relays, propulsion enhancements, or networked systems that expand operational reach, endurance, and mission duration. Together, these areas represent the spectrum of component and subsystem innovation needed to enhance LUCAS performance, reduce lifecycle costs, and enable scalable production across multiple mission sets.

l) Swarm & Collaborative Autonomy: Distributed sensing, mesh networking, cooperative tasking, and multi-vehicle behaviors.

m) Safety, Reliability & Self-Diagnostics: Pre-flight auto-check systems, onboard selfassessment tools, safe-to-arm mechanisms, and lightweight encryption modules.

n) Launch & Recovery Innovations: Low-cost launch systems, expeditionary recovery kits, modular or disposable launch rails, and ruggedized capture solutions.

o) Environmental Hardening & Weatherization: Corrosion protection, weatherproofing, low-temperature battery chemistry, and ruggedized housings.

Are there any additional benefits I would receive?

Yes. Selected companies may receive:

• Direct collaboration with LUCAS manufacturer (Spektreworks) or integrator (Neany)

• Access to government-provided interfaces, labs, and test environments (post down-select)

• Opportunity for follow-on funding for testing or production

• Exposure to multiple government stakeholders reviewing submissions on a rolling basis

What is the timeline to apply and when would I receive funding?

• Application window: open for one hundred twenty days from posting

• Submission reviews: weekly

• Down-select decisions: typically within thirty to forty-five days of submission

• Post-award expectation: solutions should be ready for demonstration within ninety days of award

Funding timing beyond this is not specified in the solicitation.

Where does this funding come from?

Funding is issued through:

• One Nation Innovation (ONIX) Other Transaction Authority (OTA)

• Operated on behalf of government partners, with coordination from OUSD R&E

Who is eligible to apply?

The challenge is broadly open to:

• Small and nontraditional vendors

• Startups and early-stage companies

• Commercial dual-use developers

• International partners (subject to regulations)

No prior DoD experience is required.

What companies and projects are likely to win?

Competitive submissions will:

• Demonstrate clear cost reduction or cost-per-effect improvements

• Be ready for testing within ninety days of award

• Integrate easily with government systems and open interfaces

• Show manufacturability, scalability, and supply chain resilience

• Provide a credible delivery schedule and transition pathway

Evaluation prioritizes:

• Open architecture and interoperability

• Cost and total ownership impact

• Technical maturity and readiness

• Integration simplicity and safety

• Speed to delivery

Are there any restrictions I should know about?

• This challenge does not fund full LUCAS aircraft development—components only

• Work is expected to be unclassified, but may involve export control or CUI compliance

• CUI cannot be submitted through the platform

• Vendors are responsible for regulatory compliance

• Selected vendors may receive controlled government data post down-select

How long will it take me to prepare an application?

The solicitation requires:

• A proposal of no more than 10 pages in 12-point Arial

• A separate cover page with company and contact details

Required content includes:

• Technical approach and cost reduction strategy

• Integration and testing plan

• Rough order of magnitude pricing

• Past performance

• Delivery schedule

Preparation time is not specified in the solicitation.

How can BW&CO help?

BW&CO can:

• Position your component against LUCAS evaluation criteria

• Translate your technology into a clear cost-reduction and integration narrative

• Align your proposal with OTA expectations and rapid prototyping goals

• Develop a compelling, compliant 10-page submission optimized for fast down-select

Additional Resources

Review solicitation here.

Fort Stewart & Hunter Army Airfield Energy Resiliency Microgrid Prototype & Lines of Effort (LOEs) Challenge through ONIX OTA Partnership

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The USARMY – Fort Stewart & Hunter Army Airfield Energy Resiliency Microgrid Prototype is a prototype-focused opportunity to design, build, and validate a solar-plus-storage microgrid supporting mission-critical operations. The Army is seeking solutions that can demonstrate real-world resiliency performance and produce a replication package for future deployments.

Applications close May 19, 2026 at 07:00 PM.

This is a fast-moving opportunity with a 30–45 day anticipated down-select, requiring concise (2–10 page) submissions and a clear, executable approach.

How much funding would I receive?

Funding typically ranges from $500k - $5m per award.

AREAS OF INTEREST

LOE 1: Prototype / Program Management, Permitting, and Stakeholder Coordination

Provide program management and dedicated oversight to execute the Fort Stewart microgrid prototype, including end‑to‑end coordination of permitting and stakeholder actions required for successful deployment.

● Provide program management, schedule/risk governance, and coordination to execute the Fort Stewart microgrid prototype within the Government-directed timeline.

● Lead and track permitting actions for the solar farm and adjacent battery facility (BESS); coordinate documentation packages and approvals with installation stakeholders and authorities having jurisdiction, as directed.

● Maintain an integrated risk register and readiness gates for design, permitting, installation, commissioning, and testing; provide recurring status reporting and issue resolution as directed.

● Coordinate site access, safety planning, and installation coordination actions required to enable on‑site work and testing activities, as directed.

LOE 2: Prototype / Microgrid Design, Build, Integration, and Commissioning (Fort Stewart)

Execute the Fort Stewart solar-plus-storage microgrid prototype to validate installation energy resiliency under outage/degraded-grid conditions, while coordinating required permitting and stakeholder actions to enable successful deployment.

● Design and implement the solar‑plus‑storage microgrid architecture, including interconnection, controls, protection schemes, and operating modes necessary to support mission‑essential loads during outages/degraded grid conditions, as directed.

● Install, integrate, and commission the solar farm and battery energy storage system (BESS), and deliver as‑built documentation and configuration baselines for the prototype system.

● Coordinate construction/installation sequencing with Government stakeholders to support access, safety, and continuity of installation operations, as directed.

● Prepare commissioning checklists and acceptance test procedures consistent with Government-directed requirements; document results and corrective actions through closeout.

LOE 3: Prototype / Performance Validation, Sustainment Readiness, and Replication Package (HAAF)

Validate prototype performance through representative testing, deliver sustainment readiness artifacts, and provide a replication kit to accelerate sequential deployment at Hunter Army Airfield.

● Execute a Government‑approved demonstration plan that includes at least one planned utility‑outage/islanding demonstration and one degraded‑grid scenario; document results, constraints, and recommended design/process changes.

● Establish baseline resiliency performance and report measurable deltas from testing (e.g., critical load support duration, transfer time to islanded operations, system availability/uptime, recovery time), with decision‑quality evidence suitable to inform sequential deployment.

● Deliver operator/maintainer training, safety procedures, sustainment recommendations, and turnover artifacts required for continued operations, as

directed.

● Deliver a microgrid replication kit to accelerate sequential deployment at Hunter Army Airfield, including process map, permitting playbook, reference

architecture, commissioning checklist, operator training package, and lessons‑learned delta list.

● Coordinate with the Government to define the mission-essential load set and target sustainment duration for demonstration events prior to execution, as directed.

Are there any additional benefits I would receive?

Yes—non-dilutive and strategic benefits include:

• Opportunity to deliver a first-of-its-kind microgrid at Fort Stewart

• Positioning for follow-on deployment at Hunter Army Airfield (approximately 1+ year out)

• Creation of a replicable implementation package for future Army installations

• Direct engagement with the U.S. Army and ONI through an ONIX OTA contracting pathway

What is the timeline to apply and when would I receive funding?

• Application deadline: May 19, 2026 at 07:00 PM

• Down-select timeline: ONI anticipates 30–45 days from posting

• Project duration: Approximately 1–1.5 years for Fort Stewart execution

Timing for award and funding disbursement is not specified in the solicitation.

Where does this funding come from?

• U.S. Army (Fort Stewart & Hunter Army Airfield)

• Contracting via ONIX OTA in coordination with ACC-RI

Who is eligible to apply?

• U.S.-based industry (i.e., small businesses), academic, and nonprofit organizations

• Must register and submit via https://gocolosseum.org

What companies and projects are likely to win?

Proposals will be evaluated across four weighted categories:

1. Technical Approach & Design (30%)

• Strong solar + battery integration design

• Clear outage/islanding capability

• Robust permitting and compliance strategy

2. Execution Capability & Schedule (25%)

• Realistic 1–1.5 year execution plan

• Defined staffing and resource allocation

• Credible cost and milestone structure

3. Deliverables & Outcomes (30%)

• Demonstrable performance metrics (e.g., load support duration, uptime)

• Complete replication package

• Strong sustainment readiness documentation

4. Past Performance & Organization Capability (15%)

• Relevant microgrid or energy resiliency experience

• Experience working on military or government installations

Are there any restrictions I should know about?

• This is a prototype-focused effort; recurring environmental compliance services are not intended unless explicitly directed

• Submission format is flexible, but proposals must include required elements (e.g., technical approach, schedule, costs, deliverables)

• Responses must be 2–10 pages maximum

How long will it take me to prepare an application?

The solicitation requires a short response (2–10 pages) including technical, cost, and execution details.

Typical preparation effort will depend on readiness, but the required components include:

• Technical approach

• Schedule and milestones

• Cost estimate (ROM)

• Past performance

• Company information

How can BW&CO help?

BW&CO can support:

• Translating your microgrid solution into a clear, evaluation-aligned proposal

• Structuring your response to directly match the scoring rubric (technical, execution, outcomes, past performance)

• Developing a credible ROM cost model and milestone plan

• Positioning your team’s experience for DoD evaluators and OTA pathways

Additional Resources

Review solicitation here.

AIR COMBAT COMMAND A2 & AIR FORCE INTELLIGENCE COMMUNITY (ACC/A2 & AF IC) COMMERCIAL SOLUTIONS OPENING (CSO) SOLICITATION NUMBER: FA7037-26-S-C001

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

This is an Air Combat Command A2 & Air Force Intelligence Community (ACC/A2 & AF IC) Commercial Solutions Opening (CSO) seeking innovative commercial technologies to support intelligence, AI, cyber, and multi-domain operations.

Important: You cannot apply yet. This is an umbrella CSO with Calls, meaning proposals are only accepted when specific Calls are released. Unsolicited proposals are not accepted.

The CSO is open-ended and allows Calls to be issued indefinitely with annual updates.

How much funding would I receive?

Funding typically ranges from $500k - $5m per award.

AREAS OF INTEREST

TOPIC 001: Data, Artificial Intelligence, and Decision Dominance

AI-Driven Predictive Intelligence Analysis

AF IC seeks solutions that leverage Artificial Intelligence and Machine Learning (AI/ML) to move from a reactive to a predictive intelligence posture. Capabilities should include the autonomous analysis of multi-intelligence (multi-INT) data to anticipate adversary actions, identify emerging threats, and drastically reduce the time required to generate and disseminate tactical intelligence.

Human-Machine Teaming for Accelerated Sense-Making

To overcome information overload, AF IC seeks intuitive platforms that enable seamless collaboration between human analysts and AI agents. The Government is interested in solutions that augment human cognition, automate laborious tasks, and utilize advanced visualization to help analysts make sense of vast, complex datasets at machine speed.

Commercial Data Integration and Analysis

AF IC requires innovative methods and platforms to rapidly identify, vet, ingest, and integrate commercially available information and data streams into our intelligence workflows. This includes, but is not limited to, commercial satellite imagery, Radio Frequency (RF) sensing data, public records, and internet-of-things (IoT) data to enrich and add context to classified intelligence.

Information Operations and Counter-Disinformation

AF IC seeks solutions capable of monitoring the global information environment to detect, analyze, and track adversary propaganda and disinformation campaigns. Key capabilities include sentiment analysis, source attribution, and the generation of data-driven counternarratives to ensure information superiority.

TOPIC 002: All-Domain Command & Control

Joint All-Domain Command and Control (JADC2), Data Integration and Fusion

To realize the vision of AF IC, the JADC2 needs a robust "digital backbone" to fuse data from disparate sensors and platforms across all domains. The Government seeks solutions for a common data layer that can normalize, process, and share Intelligence, Surveillance, and Reconnaissance (ISR) data in a secure, resilient, and cloud-native environment to create a common operating picture.

Multi-Domain Operations (MDO) Battle Management

AF IC is interested in advanced battle management tools that enable the planning, 6 coordination, and synchronized execution of multi-domain operations. Solutions should provide the Government with decision-making aids to understand the cross-domain impacts of kinetic and non-kinetic effects in a dynamic environment.

Digital Twin and Engineering for Mission Rehearsal, Tactics Development, and Training

AF IC seeks to create a high-fidelity, continuously updated digital twin of the battlespace. The primary purpose of this environment is to enable the testing of tactics, rapid development and validation of new Tactics, Techniques, and Procedures (TTPs), and advanced mission rehearsal for aircrews, operators, and planners in complex, multidomain contingencies, thereby improving readiness while reducing risk.

TOPIC 003: Resilient Cyber and Intelligence, Surveillance, Reconnaissance Operations

Advanced Sensing and Data Processing at the Edge

As operations expand into contested, communication-denied environments, the Government requires solutions that enable the processing, exploitation, and dissemination (PED) of sensor data at the tactical edge. AF IC is interested in low Size, Weight, and Power (low-SWaP) hardware and software that can perform on-platform AI/ML inference to deliver time-sensitive intelligence directly to the warfighter.

Advanced Cyber Threat Intelligence

To proactively defend our networks, the Government seeks predictive analytic platforms that can identify emerging cyber threats, TTPs, and malware before they are used against government systems. Solutions should provide actionable, machine-readable threat intelligence that can be automatically ingested by government defensive cyber platforms.

Quantum-Resistant Cryptography and Secure Communications

AF IC requires a layered defense to detect, track, identify, and neutralize hostile Small Unmanned Aerial Systems (sUAS) threats. The Government is soliciting for commercial solutions for all aspects of the counter sUAS mission, including passive and active sensors, command and control integration, and kinetic and non-kinetic effectors.

Signals Intelligence (SIGINT) Modernization

AF IC seeks to modernize government SIGINT capabilities with commercial technologies that leverage software-defined radios (SDR), advanced signal processing, and AI/ML for automated signal detection, classification, and geolocation across a congested and contested electromagnetic spectrum.

Cognitive Electronic Warfare (EW)

AF IC seeks to modernize our SIGINT capabilities and develop a cognitive EW capability that leverages AI/ML for automated signal detection, classification, and geolocation. The Government is interested in software-defined systems that can autonomously sense and dynamically respond to novel threats across a congested and contested electromagnetic spectrum.

TOPIC 004: Foundational Digital Infrastructure

Multi-Cloud Abstraction, Orchestration, and FinOps for C2E

The AF IC operates in a multi-cloud environment via the Intelligence Community's Commercial Cloud Enterprise (C2E) contract. The Government seeks a common abstraction layer or Cloud Management Platform (CMP) to provide a "single pane of glass" for managing, deploying, and securing applications across multiple classified cloud providers. Key capabilities include Infrastructure-as-Code (IaC) portability, unified security governance, and a robust Financial Operations (FinOps) dashboard to optimize cloud spending across the enterprise.

TOPIC 005: Enterprise Wide Integration and Architecture Modernization

The ACC/A2 seeks innovative solutions to support the integration of data across disparate monitoring phenomenologies and modernization of hardware/software architectures. This topic includes:

• New solutions to integrate data access and discoverability across varying monitoring phenomenologies to lower detection thresholds and/or increase efficiency of current operations.

• Technologies to modernize hardware/software architectures or implement improved software design and accrediting processes to more flexibly meet mission needs.

TOPIC 006: Enterprise Asset and Lifecycle Management Improvements

The ACC/A2 seeks innovative solutions that can provide enterprise-wide asset management visibility as well as improve our lifecycle management capabilities. This topic includes:

• Increase accuracy of forecasting of requirements and scheduling of procurements through the use and exploitation of supply chain demand data

• Supply chain management, specifically: Automated systems to reduce/eliminate inefficiency, improve asset control, decrease touchpoints and minimize inventory

• Automated identification and reporting of components and systems with substandard reliability

Are there any additional benefits I would receive?

The CSO states potential for:

• Contracts or Other Transaction Agreements (OTAs)

• Follow-on increases in award value and scope as solutions mature

What is the timeline to apply and when would I receive funding?

A deadline is to be released in the coming days. We’re planning to assist companies with meeting appropriate personnel and are beginning that work promptly.

Where does this funding come from?

• Air Combat Command A2 (ACC/A2)

• Air Force Intelligence Community (AF IC)

• Authorized under:

  • 10 U.S.C. 3458

  • R-DFARS 212.70

Who is eligible to apply?

For Step Two (full proposal), offerors must:

• Be registered in SAM.gov

• Be considered responsible under federal regulations

• Have a satisfactory performance record

• Be eligible under federal law

The solicitation references:

• Small businesses

• Nontraditional defense contractors (as defined in 10 U.S.C. § 2302(9))

What companies and projects are likely to win?

Based on the solicitation, competitive solutions will:

• Be innovative (new or new application of existing tech)

• Be commercial or commercializable

• Align directly with AF IC mission needs

• Be built for:

  • Cloud-native environments

  • AI-enabled workflows

  • Secure, scalable deployment

Strong proposals will also demonstrate:

• Integration with Zero Trust and ICAM

• Compatibility with DevSecOps and continuous ATO (cATO)

• Use of open architectures (SOSA / OMS)

Are there any restrictions I should know about?

Yes:

• Unsolicited proposals will not be accepted

• Do not submit proprietary, classified, or sensitive information in responses

• Must comply with:

  • Cybersecurity requirements (CMMC levels per Call)

  • SAM registration and UEI requirements

Other constraints:

• Government may award all, part, or none

• Government is not obligated to make any award

• Offerors bear all proposal preparation costs

How long will it take me to prepare an application?

The structure implies:

• White Paper (2–5 pages) + Quad Chart for Step One

• Full proposal only if invited

Actual timelines will be defined in each Call.

How can BW&CO help?

BW&CO can support you to:

• Monitor and identify relevant Calls as soon as they are released

• Shape your solution to align with:

  • AF IC priority topics

  • Zero Trust, DevSecOps, and open architecture requirements

• Develop:

  • High-impact white papers and quad charts

  • Full proposals for Step Two

• Position your company as a credible commercial partner to DoD/IC buyers

Additional Resources

Review solicitation here.

Defense Industrial Base Consortium (DIBC) -Industrial Base Analysis and Sustainment (IBAS) - RFP 26-01

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Defense Industrial Base Consortium (DIBC) is soliciting prototype solutions to address critical domestic supply chain vulnerabilities and manufacturing capability gaps across four priority areas. These efforts are funded under the Industrial Base Analysis and Sustainment (IBAS) program using RDT&E appropriations and are tied to Congressional Interest.

Companies should move quickly if aligned—this is a targeted, single-award-per-topic opportunity with defined funding ceilings and strong Government interest in scaling domestic capacity.

How much funding would I receive?

Funding is structured as single awards per topic, each capped at the following levels:

• Topic 1: Secure Processor Development — Up to $8,300,000 (RDT&E)

• Topic 2: Rare Earth Magnet Manufacturing — Up to $2,500,000 (RDT&E)

• Topic 3: Industrial Forge Quenching Capacity Improvement — Up to $2,500,000 (RDT&E)

• Topic 4: RF Contested Environments — Up to $4,400,000 (RDT&E)

The Government intends to make one award per topic, not exceeding the stated funding limitation.

RESEARCH TOPICS:

• Topic 1: Secure Processor Development

  The Government requires a prototype project to develop, mature, and scale the domestic production of advanced secure processors for defense applications. Modern defense systems operating at the tactical edge require high-performance computing (eg, AI/ML processing, sensor fusion) while maintaining an absolute Zero-Trust hardware posture. Current commercial-off-the-shelf (COTS) processors are vulnerable to supply chain interdiction, side-channel attacks, and reverse engineering.

  • Technical Focus: Solutions should emphasize hardware roots of trust (RoS), secure boot mechanisms, inline memory encryption, and resistance to physical and electrical side-channel attacks. Proposals may include advanced 2.5D and 3D heterogeneous integration (HI) packaging, or the integration of secure processor chiplets (such as RISC-V architectures with integrated memory guards) into larger systems on a chip (SoC).

  • Funding Limitation: Up to $8,300,000 (RDT&E). The Government intends to make a single award no greater than the funding limitation. Teaming arrangements are acceptable and encouraged to meet complex supply chain requirements.

• Topic 2: Rare Earth Magnet Manufacturing

  The Government requires prototype solutions to establish or enhance domestic manufacturing capabilities for high-performance rare earth permanent magnets, specifically Neodymium-Iron-Boron (NdFeB) and Samarium-Cobalt (SmCo). These magnets are critical for defense electric drive systems, radar, missile guidance fins, and advanced actuators (e.g., F-35 and submarine platforms). Currently, foreign entities of concern control over 85% of the global magnet processing and production capacity.

  • Technical Focus: The project must advance a verifiable, secure "mine-to-magnet" supply chain completely bypassing foreign entities of concern. The project may use virgin material sources or recycled materials. Technical approaches should highlight advanced sintered manufacturing processes, heavy rare earth (HRE) separation capabilities (specifically isolating Dysprosium and Terbium), or the use of Grain Boundary Diffusion (GBD) technology to maximize high-temperature performance while reducing overall reliance on scarce HREs.

  • Funding Limitation: Up to $2,500,000 (RDT&E). The Government intends to make a single award no greater than the funding limitation. Teaming arrangements are acceptable and encouraged to meet complex supply chain requirements.

  • Economic Participation: To ensure a resilient domestic supply chain, the Government seeks solutions demonstrating shared financial investment and long-term commercial sustainment. In alignment with the IBAS mission to establish and diversify regional centers of excellence, the Government will favorably evaluate proposals that build or utilize robust industrial infrastructure, integrate localized supply chains, and develop specialized workforces for domestic magnet manufacturing. The highest evaluation preference will be given to proposed solutions that strategically locate operations within established or rapidly emerging U.S. automotive, aerospace, or advanced manufacturing corridors to leverage existing industrial synergies."

• Topic 3: Industrial Forge Quenching Capacity Improvement

  Heavy forging is a foundational requirement for major defense platforms, particularly within the Submarine Industrial Base (SIB), shipbuilding, and heavy armor. The Government requires a prototype project to design, upgrade, and validate improved industrial forge quenching capacity. Current domestic infrastructure is a major bottleneck, leading to extended lead times for ultra-large cast and forged components.

  • Technical Focus: Solutions must demonstrate the implementation of advanced quenching infrastructure (eg, large-scale water, oil, or polymer quench tanks). The technical approach should feature automated, sensor-driven temperature monitoring and controlled cooling rates to guarantee metallurgical consistency, prevent stress fractures in heavy steel/titanium alloys, and significantly increase throughput for Navy and Army platform components.

  • Funding Limitation: Up to $2,500,000 (RDT&E). The Government intends to make a single award no greater than the funding limitation. Teaming arrangements are acceptable and encouraged to meet complex supply chain requirements.

  • Economic Participation: To meet the IBAS strategic requirement for expanding geographically distinct heavy industrial infrastructure, the Government seeks proposals that drive direct economic participation and localized industrial impact. The highest evaluation preference will be given to proposed solutions that establish or expand operations within regions offering established heavy manufacturing ecosystems, high-capacity energy grids, and strategic logistical access to rapidly scale domestic infrastructure capabilities."

• Topic 4: RF Contested Environments

  The Department of War (DoW) requires domestic, trusted prototyping and low-rate initial production of advanced microelectronics capable of maintaining spectrum dominance in severely contested and congested electromagnetic environments.

  Currently, the U.S. Defense Industrial Base (DIB) faces a critical gap in fielding ultra-wideband, low-latency RF signal processing components at the tactical edge. Near-peer adversaries have proliferated sophisticated Electronic Warfare (EW) systems designed to jam, spoof, or degrade DoW communications, radar, and precision-guided munitions. Existing silicon-based microelectronics lack the instantaneous bandwidth and dynamic range required to filter intentional interference and isolate signals of interest in real-time, posing a severe risk to Joint All-Domain Command and Control (JADC2) survivability.

  ·         Technical Focus: The solution must be centered on the design, development, and prototyping of advanced microelectronic architectures capable of maintaining spectrum dominance in highly contested and congested Radio Frequency (RF) environments. To counter sophisticated near-peer Electronic Warfare (EW) and jamming capabilities, the proposed solution must deliver ultra-wideband signal processing beyond the state of the practice at the tactical edge. This requires moving beyond traditional narrowband, high-latency digital conversion by integrating analog, mixed-signal, or photonic pre-processing directly on-chip. These advanced microelectronic components must demonstrate the high dynamic range necessary to simultaneously nullify high-power, frequency-hopping interference while isolating and preserving critical, low-power signals of interest in real-time without introducing processing lag.

  Furthermore, the technical focus mandates strict adherence to Size, Weight, Power, and Cost (SWaP-C) optimization to ensure the resulting prototypes are viable for integration into constrained platforms such as Unmanned Aerial Systems (UAS), precision-guided munitions, and mobile Joint All-Domain Command and Control (JADC2) nodes. A critical execution requirement of this effort is the active utilization and maturation of the domestic supply chain, specifically leveraging the established optics, photonics, and RF microelectronics industrial base. Performers must explicitly demonstrate how their technical approach integrates specialized manufacturing, advanced prototyping, and research capabilities to deliver military-grade, environmentally hardened sub-systems (targeting Technology Readiness Level 5 or 6) that are ready for transition into Department of War (DoW) Programs of Record.

  • Funding Limitation: Up to $4,400,000 (RDT&E). The Government intends to make a single award no greater than the funding limitation. Teaming arrangements are acceptable and encouraged to meet complex supply chain requirements.

Are there any additional benefits I would receive?

This program is structured around Government equity, meaning participation may include:

• Government Purpose Rights (GPR) to technical data and software

• Priority access or reserved production capacity

• Delivery of prototypes, tooling, or LRIP units

• Shared licensing or royalty-free use of developed IP

Additionally, projects are tied to Congressional Interest and may position companies for future defense production and transition opportunities.

What is the timeline to apply and when would I receive funding?

A deadline is to be released in the coming days. We’re planning to assist companies with meeting appropriate personnel and are beginning that work promptly.

Where does this funding come from?

Funding comes from:

• Research, Development, Test, and Evaluation (RDT&E) appropriations

• Managed under the Industrial Base Analysis and Sustainment (IBAS) program

• Executed through the Defense Industrial Base Consortium (DIBC)

These efforts are explicitly tied to national security priorities and Congressional Interest.

Who is eligible to apply?

• Members of the Defense Industrial Base Consortium (DIBC) may submit solution papers

• Teaming arrangements are acceptable and encouraged

No additional eligibility criteria are specified in the solicitation.

What companies and projects are likely to win?

Competitive proposals will:

• Directly address critical supply chain vulnerabilities

• Demonstrate ability to scale domestic manufacturing capacity

• Align tightly with IBAS objectives

• Show regional industrial impact and infrastructure development

• Include shared financial investment and long-term sustainment plans (where applicable)

• Leverage or build localized supply chains and workforce development

Highest preference is given to projects that:

• Strengthen regional industrial hubs

• Integrate into existing U.S. automotive, aerospace, or manufacturing corridors

• Reduce reliance on foreign entities of concern

All topics are evaluated independently.

Are there any restrictions I should know about?

Key requirements and constraints include:

• The Government expects equity commensurate with its investment

• Projects must align with IBAS statutory objectives

• Solutions must support domestic supply chain resilience

• Certain topics require fully domestic supply chains bypassing foreign entities of concern

• Deliverables may include data rights, IP access, and production commitments

Additional topic-specific technical constraints apply (e.g., SWaP-C requirements, secure architectures, metallurgical controls).

How long will it take me to prepare an application?

Not specified in the solicitation.

How can BW&CO help?

BW&CO can support:

• Opportunity qualification and topic alignment strategy

• Structuring competitive Solution Papers

• Positioning your project for IBAS evaluation criteria

• Building teaming strategies and supply chain narratives

• Translating technical concepts into clear, fundable proposals

Additional Resources

Review solicitation here.

U.S. DOT SBIR Fiscal Year 2026 (FY26) Phase I

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The U.S. DOT SBIR FY26 Phase I Pre-Solicitation is now open and represents an early opportunity to align with upcoming federal R&D funding across transportation, AI, safety, and infrastructure.

The pre-solicitation is open through May 29, 2026, at 5:00 p.m. ET, which is the key near-term deadline to engage, ask questions, and position your solution.

While this is not the formal application window, companies that act now—by refining their concept, engaging in Q&A, and aligning to specific topics—will be significantly better positioned for the estimated solicitation period: June 3, 2026 – July 7, 2026.

How much funding would I receive?

Phase I funding is up to $200,000 for 6 months.

RESEARCH TOPICS:

• 26-FH1: Edge AI-V2X Integrated Practical Solutions for Congestion Prevention and Mitigation

  This topic seeks an integrated system combining AI, edge/cloud computing, and V2X communication to detect, predict, and mitigate traffic congestion in real time across multiple intersections or regions. The solution should ingest diverse traffic data, generate location-specific operational guidance (e.g., speed, lane changes, detours), and securely deliver it to vehicles, infrastructure, and agencies. A key focus is on balancing workloads between edge and cloud systems while ensuring low latency, scalability, and secure communications.

• 26-FH2: Automated Mobile Catch-basin Inspection System

  FHWA is looking for a vehicle-mounted, multi-sensor inspection system that can assess catch-basin conditions (e.g., water, sediment, debris) without removing grates or requiring manual inspection. The system should use sensors (optical, lidar, radar, etc.) and AI to interpret basin conditions while in motion, improving safety and efficiency for DOTs managing large, distributed infrastructure networks.

• 26-FR1: Mobile High-Power Emergency BESS De-energizer System for Rail Vehicle Propulsion

  This topic calls for a mobile system capable of safely discharging high-voltage lithium-ion battery systems (BESS) in rail vehicles after accidents or during maintenance. The system must handle at least 400 kW of stored energy, include robust safety features, and be operable by trained personnel. It should support multiple discharge methods (resistive, regenerative, or hybrid) and integrate with emergency response and rail maintenance workflows.

• 26-FT1: Person-Centered, Carefree, Complete Trip Planning - Powered by AI

  FTA seeks an AI-powered trip planning tool that supports the entire “Complete Trip,” from deciding to use transit through navigation and adaptation during travel. The system should integrate multimodal transportation data, personalize recommendations based on user preferences, and ensure accessibility for all users, including those with disabilities. The goal is to make transit a seamless, intuitive option compared to other modes.

• 26-OS1: Predictive Safety Analytics for Commercial Transport Modernization

  This topic focuses on developing predictive analytics tools that use AI and integrated data sources to proactively identify safety risks in commercial transportation. A core component is a “Trusted Intermediary” framework that securely combines private industry data with public datasets while preserving privacy. The system should generate actionable, explainable insights to improve safety outcomes and resource allocation.

• 26-OS2: Freight Corridor Predictive Intelligence

  This topic seeks an AI-enabled system that predicts freight bottlenecks and supply chain disruptions using multimodal data, edge analytics, and federated learning. The solution should provide real-time insights and decision-support tools for public and private stakeholders, including dashboards and alerts. It aims to improve corridor efficiency, resilience, and coordination across transportation systems.

• 26-PH1: Increase End-of-Life Battery Safety and Recovery of Rare Earth Minerals

  PHMSA is looking for a safe, fast, and cost-effective method to remove residual energy from end-of-life lithium-ion batteries, reducing explosion risk during transport. The solution should enable safer shipping and improve the economics of recovering critical minerals, with potential to support regulatory changes and broader commercialization.

• 26-PH2: Thermal Indicator Coatings for Hazardous Materials Packaging Safety

  This topic seeks a thermochromic coating for hazardous materials packaging that visibly changes color when internal temperatures reach dangerous levels. The coating should be durable, low-cost, and compatible with various packaging materials, providing first responders and operators with a clear, intuitive warning signal during transport or emergencies.

• 26-PH3: Self-repairing Hazardous Materials Packaging

  PHMSA is interested in self-repairing materials or coatings that can automatically fix damage (e.g., cracks, corrosion, punctures) in hazardous materials packaging. The solution must meet existing regulatory standards and improve safety, durability, and cost-effectiveness across bulk and non-bulk packaging applications.

• 26-PH4: Improved Response to Lithium-ion Battery Fires

  This topic calls for a low-cost, easy-to-deploy solution to suppress lithium-ion battery fires quickly and prevent reignition. The system should work across different battery types and scenarios, integrate with emergency response workflows, and be scalable for widespread use by first responders, shippers, and operators.

Are there any additional benefits I would receive?

Not explicitly specified, but the document indicates:

• Opportunities to work with federal agencies and transportation operators

• Potential pilot deployments with state/local partners

• Path to Phase II funding for prototype development and validation

• Early positioning in priority areas like AI, safety, and infrastructure modernization

What is the timeline to apply and when would I receive funding?

Key dates provided:

• Pre-solicitation open through May 29, 2026, at 5:00 p.m. ET

• Pre-solicitation Q&A period: April 29, 2026 – May 29, 2026 at 5:00 p.m. ET

• Estimated solicitation period: June 3, 2026 – July 7, 2026

Funding timing after submission is not specified in the provided materials.

Where does this funding come from?

Funding comes from the U.S. Department of Transportation (U.S. DOT) SBIR program, including:

• Federal Highway Administration (FHWA)

• Federal Railroad Administration (FRA)

• Federal Transit Administration (FTA)

• Office of the Secretary (OST)

• Pipeline and Hazardous Materials Safety Administration (PHMSA)

Who is eligible to apply?

• For-profit small businesses

What companies and projects are likely to win?

Based on the topic descriptions:

• Companies building real, testable systems (not just concepts)

• Teams that integrate:

  • AI + real-world data

  • Hardware + software systems

  • Existing infrastructure (e.g., V2X, sensors, rail systems)

• Proposals that demonstrate:

  • Clear Phase I feasibility approach

  • Path to Phase II deployment

  • Partnerships with agencies or industry stakeholders

• Solutions that address:

  • Safety, reliability, and scalability

  • Real-world operating constraints (latency, environment, compliance)

  • Human usability and adoption

Are there any restrictions I should know about?

Examples from the topics include:

• Must integrate with existing infrastructure and systems

• Must meet safety, regulatory, and operational requirements

• Some topics require industry partnerships (e.g., rail stakeholders)

• Certain exclusions apply (e.g., radioactive materials excluded in PHMSA 26-PH3)

• Solutions must be practical, scalable, and deployable

How long will it take me to prepare an application?

Given the timeline:

• You effectively have until July 7, 2026 (estimated) to prepare for submission once the solicitation opens

• Early preparation during the pre-solicitation period (through May 29, 2026, at 5:00 p.m. ET) is strongly implied

How can BW&CO help?

BW&CO can help you:

• Select the right topic across FHWA, FRA, FTA, OST, and PHMSA

• Translate your product into a Phase I-ready technical concept

• Build a clear commercialization and Phase II pathway

• Develop a competitive SBIR proposal aligned to DOT expectations

• Use the pre-solicitation window to refine positioning and de-risk your application

Additional Resources

Review solicitation here.

Department of Education - SBIR/STTR Opportunities (IA, IB, and DT2)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The U.S. Department of Education (ED), through the Institute of Education Sciences (IES), is offering three SBIR funding tracks in 2026: Phase IA, Phase IB, and Direct to Phase II. These programs fund education technology companies at different stages—from early prototype to full-scale commercialization.

• Phase IA: Build a brand-new product (early-stage)

• Phase IB: Improve an existing product (mid-stage)

• Direct to Phase II: Scale a proven innovation (late-stage)

All three tracks are competitive and mutually exclusive (you cannot submit the same or similar proposal across tracks).

Application deadline: June 29, 2026 at 11:00 a.m. Eastern Time (ET) for Phase IA and IB, and June 29, 2026 at 2:00 p.m. Eastern Time (ET) for Direct to Phase II.

How much funding would I receive?

• Phase IA: $250,000 for 9 months

• Phase IB: $250,000 for 9 months

• Direct to Phase II: $1,000,000 for 2 years

What could I use the funding for?

Across all three tracks, funding supports:

• Research and development (R&D)

• Product development

• Pilot testing with users

• Data collection and analysis

• Personnel and subcontractors

Key differences:

• Phase IA: Build a new prototype from scratch

• Phase IB: Develop a new component integrated into an existing product

• Direct to Phase II:Scale and commercialize an existing evidence-based innovation

Are there any additional benefits I would receive?

• Phase IA and IB awardees can apply for $1,000,000 Phase II funding the following year

• All tracks provide federal validation and commercialization support

• Direct to Phase II provides immediate access to $1M scale funding without Phase I

What is the timeline to apply and when would I receive funding?

Application timeline:

• White Papers per Program: Continuous, after the posting of Q&As (Preferred)

• Full proposals: By invitation only

Process:

1. Submit White Paper

2. Government evaluates for viability

3. If selected → invited to submit full proposal

4. If selected → negotiation → award

Award timing:
Not specified in the solicitation.

Where does this funding come from?

• U.S. Department of Education (ED)

• Institute of Education Sciences (IES)

• Small Business Innovation Research (SBIR) Program

Who is eligible to apply?

• For-profit small businesses

Track-specific requirements:

• Phase IA: Little or no prior product development

• Phase IB: Must have an existing functioning prototype or product

• Direct to Phase II: Must work with an existing evidence-based innovation developed by a university or nonprofit and include the original researcher on the team

What companies and projects are likely to win?

• Phase IA: Novel, high-risk ideas with strong potential impact

• Phase IB: Companies with working products and a clear, innovative upgrade

• Direct to Phase II: Teams with strong research evidence and a credible plan to scale

Across all tracks:

• Clear problem-solution fit

• Strong research and technical approach

• Path to commercialization

Are there any restrictions I should know about?

• Cannot submit the same or similar proposal across Phase IA, IB, or Direct to Phase II

• Phase IA: Must be a new, independent product

• Phase IB: New component must be distinct and not a continuation

• Direct to Phase II:

  • Innovation must be originally developed by academic or nonprofit researchers

  • Cannot already be widely deployed at scale

How long will it take me to prepare an application?

• Phase IA / IB: Typically 4–8 weeks

• Direct to Phase II: Typically 6–10+ weeks

How can BW&CO help?

BW&CO can support:

• Identify the right track (IA vs IB vs Direct to Phase II)

• Position your company and product for competitiveness

• Develop full technical, research, and commercialization narratives

• Build compliant budgets and submission packages

Additional Resources

Review solicitation here.

NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) - PA-27-100

Executive Summary:

The NIH, CDC, and FDA jointly award up to $2.1 million per company through the SBIR Program (NIH additionally runs the parallel STTR Program) to support U.S. small businesses developing innovative health, biomedical, and life science technologies. Companies can apply for Phase I (proof-of-concept), Phase II (R&D and commercialization), Fast-Track, Phase IIB (follow-on), or the Commercialization Readiness Pilot (CRP) for late-stage commercialization support. Applications are due January 5, April 5, and September 5 each year, with funding typically beginning 9 months after submission. Companies should begin preparing applications at least 12 weeks before a due date to complete required federal registrations.

Note: CDC does not accept STTR, Fast-Track, Direct-to-Phase II, Phase IIB, or CRP applications. FDA does not participate in STTR at all and does not accept Fast-Track, Direct-to-Phase II, Phase IIB, CRP, or clinical trial applications through either program.

How much funding would I receive?

Standard guidelines provide up to $323,090 for Phase I (typically 1–2 years) and $2,153,927 for Phase II (typically 2–3 years). Many NIH Institutes and Centers (ICs) have approval to exceed these caps for specific research priorities. For example:

• NIA allows up to $700,000 (Phase I) and $3 million (Phase II) for Alzheimer's disease and AD-related dementia (AD/ADRD) projects, and up to $500,000/$2.5 million for other projects in its mission space.

• NIGMS allows Phase IIB budgets up to $3 million, or $4 million for Strategic Breakthrough awards involving clinical trials.

• NCI supports CRP projects (including clinical trials and validation studies) up to the SBA statutory maximum of $4,191,495, plus up to $500,000 for technical assistance.

• NIEHS caps its Superfund Research Program topics at $200,000 (Phase I) / $1.25 million (Phase II) / $300,000 (CRP), and its Worker Training Program topics at $100,000 (Phase I only).

Fast-Track and Phase IIB options allow continuous or extended funding beyond Phase II, though acceptance of Phase IIB and CRP applications varies by Institute or Center (see below).

What could I use the funding for?

Funds support research and development toward a commercially viable product or service aligned with the mission of a specific NIH Institute or Center, CDC program, or FDA center. Eligible costs include personnel, materials, prototypes, testing, IP protection, and other R&D expenses. Phase II, Phase IIB, and CRP funds may also cover scale-up, clinical validation, regulatory preparation (including IND/IDE-enabling studies), and commercialization activities.

Does NIH SBIR/STTR fund clinical trials?

It depends on the Institute or Center. Most ICs with a direct clinical mission (NCI, NHLBI, NIA, NICHD, NIDA, NIMH, NINDS, NIMHD, NIDDK, and others) accept clinical trials through their SBIR and/or STTR programs, and several (NCI, NHLBI, NIA, NICHD, NIGMS, NIMH, NINDS, NIMHD) accept them through Phase IIB as well. A smaller number of ICs, including NIAMS, NIDCR, and NIBIB (limited to early-stage, feasibility-only trials), do not accept clinical trials or restrict them significantly. CDC accepts clinical trials through its SBIR program; FDA does not accept clinical trials through either program. Applicants planning human subjects research, including IDE- or IND-enabling studies, should confirm their target IC's specific policy and connect with program staff before submission, since sequencing (e.g., IDE/IRB timing relative to Phase I/II milestones) varies significantly by IC.

What is the Commercialization Readiness Pilot (CRP)?

CRP is a late-stage, milestone-driven award intended for companies that are close to market and need targeted, non-dilutive funding to complete specific commercialization steps, such as clinical trials, manufacturing scale-up, or regulatory submissions. Most (but not all) NIH ICs participate; CDC and FDA do not. Where offered, CRP budgets and eligible use cases vary considerably by IC, as shown above.

• National Center for Advancing Translational Sciences (NCATS)

  NCATS supports research including, but not limited to, clinical technology, instruments, devices, and related methodologies that may have broad application to clinical research and better patient care. Our interests are in four main categories

  (1) Preclinical Drug Discovery and Development

  (2) Biomedical, Clinical and Health Research Informatics

  (3) Clinical, Dissemination and Implementation Research

  (4) Rare Diseases and Unmet Needs.

  Indications Of Interest:

  • Intestinal fibrosis

  • Cardiovascular disease / cardiac regeneration

  • Cancer (including cancer immunotherapy and solid tumors)

  • Facioscapulohumeral muscular dystrophy (FSHD)

  • Primary ciliary dyskinesia

  • Pulmonary fibrosis

  • Cystic fibrosis

  • Asthma

  • Chronic obstructive pulmonary disease (COPD)

  • Non-cystic fibrosis bronchiectasis

  • Lung cancer

  • Huntington's disease (including prodromal Huntington's disease)

  • Heart failure

  • Hypertension

  • Cardiomyopathies

• National Center for Complementary and Integrative Health (NCCIH)

  The NCCIH will support applications on the development of technologies and therapies relevant to complementary and integrative approaches.

  Complementary health approaches include a broad range of practices and interventions that can be classified by their primary therapeutic input, including:

  • nutritional and natural products (e.g., special diets, dietary supplements, botanicals, probiotics, and microbial-based therapies),

  • psychological (e.g., meditation, hypnosis, music-based interventions, relaxation therapies),

  • physical (e.g., acupuncture, massage, chiropractic manipulation, other force-based manipulations, or devices related to these approaches), or

  • a combination of psychological and physical (e.g., yoga, tai chi, or some forms of art therapies, such as music-based interventions) input.

  Additionally, NCCIH will support applications that explore the impact of complementary and integrative health approaches on health promotion, resilience, and whole person health.

  Overall, NCCIH will support applications that include complementary and integrative health approaches, including multicomponent interventions that combine two or more complementary and integrative health approaches, or one or more complementary approaches integrated with one or more conventional care interventions. 

  Indications Of Interest:

  • Anxiety disorders

  • Major depressive disorder / depression

  • Stress-related psychiatric disorders

  • Chronic inflammatory disorders

  • Chemotherapy-induced nausea and vomiting (CINV)

  • Youth mental health / social isolation

• National Cancer Institute (NCI)

  NCI supports the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs by engaging domestic small business concerns in federal cancer research and development that has the potential for commercialization. 

  Indications Of Interest:

  • Skin cancer (melanoma and non-melanoma)

  • Lung cancer (including non-small cell lung cancer)

  • Liver cancer / hepatocellular carcinoma

  • Pancreatic cancer (pancreatic ductal adenocarcinoma, including mutant KRAS/RAS)

  • Prostate cancer (including metastatic castration-resistant prostate cancer)

  • Colorectal cancer (including microsatellite stable colorectal cancer)

  • Head and neck squamous cell carcinoma (HNSCC)

  • Oral / oropharyngeal squamous cell carcinoma

  • Breast cancer

  • Ovarian cancer

  • Cervical / gynecological cancer (dysplasia screening)

  • Glioblastoma / glioma / brain cancer

  • Melanoma (metastatic / Stage IV)

  • Cholangiocarcinoma

  • Multiple myeloma

  • Acute lymphoblastic leukemia (pediatric)

  • Acute myeloid leukemia (AML)

  • Lymphoma (including non-Hodgkin's lymphoma / relapsed-refractory B-cell malignancies)

  • Hereditary cancer syndromes (e.g., Lynch syndrome) / cancer previvors

  • Cancer-related fatigue and sleep disturbances (cancer survivorship)

  • Solid tumors / pan-cancer (general)

  • Diabetic foot ulcers and knee osteoarthritis (secondary indications)

  • Liver transplant ischemia-reperfusion injury / end-stage liver disease (secondary indication)

• National Eye Institute (NEI)

  NEI supports research including, but not limited to, the following:

  • Commercializable research and clinical innovations in ophthalmology and vision sciences

  • Commercializable therapeutics including drugs, biologics, devices, or combination therapeutics that prevent or reduce blindness or improve ocular health

  •  Market-ready technologies and diagnostic tools for predicting, identifying, or monitoring eye diseases and vision-related conditions

  • Commercializable devices and services that assist people with blindness or visual impairments to improve quality of life Commercial-grade devices and support services that help individuals with blindness or vision impairments to improve and enhance their daily living experience

  • Market-ready technologies that correct, enhance, or augment human vision

  Indications Of Interest:

  • Age-related macular degeneration (neovascular/wet AMD and dry AMD)

  • Dry eye disease (including Meibomian gland dysfunction)

  • Glaucoma (including post-trabeculectomy scarring and intraocular pressure management)

  • Diabetic retinopathy (including diabetic macular edema)

  • Retinitis pigmentosa / inherited retinal degeneration

  • Leber congenital amaurosis type 1 (LCA1)

  • Retinopathy of prematurity (ROP)

  • Corneal endothelial disease / Fuchs' endothelial corneal dystrophy

  • Corneal injuries and wounds (e.g., alkali burns)

  • Persistent corneal epithelial defects (PCED) / neurotrophic keratitis

  • Myopia (pediatric myopia and myopia progression)

  • Optic neuropathies / neuro-ophthalmic disease (including optic neuritis)

  • Visual impairment following traumatic brain injury (mTBI/concussion)

  • Refractive error / higher-order aberrations (contact lens correction)

  • Uveitis and ocular infections (secondary)

  • Blindness and low vision (assistive technology / accessibility focus)

• National Human Genome Research Institute (NHGRI)

  Interest Areas:

  • Significant innovations in genomic methods or technology development. This includes, but is not limited to, advancements in nucleic acid sequencing, synthetic nucleic acid synthesis, functional genomics, single cell genomic analysis, transcriptomics, multi-omics, instrumentation, or molecular kits. 

  • Tools and techniques that use genomics to improve patient health, such as approaches to incorporate genomic results into electronic medical records, clinical decision support tools, or genomic directed health care. 

  • Strategies to enhance ethical, legal, and social aspects of genomics research or translation of genomics into health care. 

  • Bioinformatics software or platforms for genomic, genetic, or sequence data processing or analysis, functional genomics, associations between genomic data and diseases or phenotypes, interpretation of variants, or genomic data integration into clinical decision making. 

  • Databases and data management platforms for genomics research and application including platforms for sequence, functional, or phenotypic data or annotation of variants. 

  • Development and application of methods for machine learning, pattern detection, or knowledge networks for genomics science or translation into health care. 

  • Informatics methods and platforms that adopt data standards, enhance data sharing with privacy, and improve data exchange in genomics science or translation of genomics into health care. 

  • Use of cloud and other computing models to improve scale, reproducibility, interoperability, cost-effectiveness, and utility of genomic and clinical data in genomics or translation into health care. 

  • Development of curriculum and educational opportunities that increase the genomics knowledge of participants at the undergraduate, postbaccalaureate, graduate, postdoctoral, or professional levels. 

• National Heart, Lung, and Blood Institute (NHLBI)

  Interest Areas:

  The National Heart Lung and Blood Institute (NHLBI) is interested in supporting the development of novel therapeutics, devices, diagnostics, digital health technologies, research tools, and other innovative solutions for advancing the prevention, diagnosis, and treatment of heart, lung, blood, and sleep (HLBS) diseases and disorders. 

  Topics of particular interest for the NHLBI SBIR/STTR program include, but are not limited to, the following topics: 

  • Technologies addressing HLBS complications relevant to maternal health and women’s health  

  • Artificial Intelligence/Machine Learning technologies to improve the diagnosis, treatment, and prevention of HLBS diseases and disorders 

  • Precision medicine approaches to treating HLBS diseases and disorders 

  • New approach methodologies, tools, and point-of-care technologies to improve detection and therapeutic development for HLBS diseases and disorders

  Indications Of Interest:

  Lung / respiratory

  • Idiopathic pulmonary fibrosis (IPF) / interstitial lung disease

  • Chronic obstructive pulmonary disease (COPD)

  • Asthma

  • Cystic fibrosis and primary ciliary dyskinesia

  • Pulmonary hypertension

  • Sarcoidosis

  • Acute respiratory distress syndrome (ARDS) / acute lung injury

  • Radiation-induced lung injury (pneumonitis/fibrosis)

  • Respiratory failure (ECMO/mechanical ventilation context)

  • Empyema / parapneumonic effusion

  • Pulmonary embolism

  • End-stage lung disease (lung transplant)

  • Other fibroses noted: scleroderma skin fibrosis, kidney fibrosis (CKD), intestinal fibrosis (Crohn's)

  Heart / cardiovascular

  • Cardiovascular disease (general risk assessment)

  • Coronary artery disease / coronary heart disease

  • Myocardial infarction / ischemic heart disease (including reperfusion injury)

  • Heart failure (including HFrEF and chronic heart failure)

  • Coronary microvascular and vasomotor dysfunction (CMVD)

  • Ventricular tachycardia / arrhythmias

  • Cardiac arrest / ventricular fibrillation (including refractory)

  • Mitral regurgitation / mitral valve disease

  • Heart valve disease (transcatheter and surgical valves)

  • Hypertrophic and dilated cardiomyopathies (HCM/DCM)

  • Hypertension

  • Congenital heart disease (including hypoplastic left heart syndrome / single-ventricle / Fontan physiology, pulmonary valve defects)

  • Infantile hemangioma

  • Abdominal and thoracic aortic aneurysm

  • Aortic dissection

  • Atrial fibrillation / stroke prevention

  • Peripheral artery disease / critical limb ischemia (CLTI)

  • Conduction system disorders / pacing (bradycardia, LV dysfunction)

  Blood / hematologic

  • Sickle cell disease / sickle cell anemia

  • Anemia

  • Hemophilia A

  • Thrombosis / clotting disorders (including catheter-related thrombosis)

  • Heparin-induced thrombocytopenia (HIT)

  • Bleeding / hemostasis (antiplatelet reversal)

  • Hematologic malignancies / blood disorders (hematopoietic stem cell transplant)

  • Neutropenia

  • Graft-versus-host disease (GVHD) / alloimmunization

  Sleep

  • Obstructive sleep apnea (infants, children, adults)

  • Central sleep apnea

  Other / cross-cutting

  • Organ transplantation (heart, lung, liver, kidney; xenotransplantation)

  • Perioperative / postoperative complications

  • Sepsis

  • PFAS exposure / cardiometabolic risk

• National Institute on Aging (NIA)

  The NIA is interested in proposals to develop and validate technologies that enhance the health and wellbeing of older adults. Areas of high interest include technologies intended to address unmet needs and have clear competitive advantages, development of commercialized solutions that are cost-effective and widely available, and small businesses that are new to SBIR/STTR funding.

  Scientific areas of interest include but are not limited to:

  Alzheimer's Disease (AD), AD-Related Dementias (ADRD), and Age-Related Cognitive Decline:

  Development of innovative tools, technologies, and interventions to prevent, diagnose, treat, monitor, or slow progression of AD/ADRD, cognitive decline, age-related sleep disorders, and delirium, including:

  • Biomarkers, research tools, diagnostics, imaging technologies, and AI/ML methods for early detection and monitoring.

  • Treatments, including cell and gene therapies, exosome-based therapeutics, behavioral and digital interventions as well as other novel approaches.

  Aging Biology and Age-Related Diseases:

  Development of technologies, therapeutics, biomarkers, and tools to measure, prevent, treat, or slow progression of age-related biobehavioral decline and conditions, including:

  • Therapeutics targeting aging biology mechanisms and personalized medicine approaches.

  • Research tools and data science technologies to understand aging and predict health outcomes.

  Aging in Place of Choice and Care Delivery:

  Development of technologies and interventions that promote healthy aging, support aging in place of choice, improve care delivery, or reduce caregiving burden, including: 

  • Assistive devices, robotics, sensors, digital health products, and technologies to enhance care.

  Indications Of Interest:

  Cognitive / neurodegenerative (the dominant focus)

  • Alzheimer's disease (diagnosis, biomarkers, therapeutics — by far the largest area)

  • Alzheimer's disease and related dementias (ADRD) / dementia generally

  • Mild cognitive impairment (MCI)

  • Lewy body disease / Lewy body pathology

  • Frontotemporal dementia (FTD)

  • Amyotrophic lateral sclerosis (ALS)

  • Limbic-predominant age-related TDP-43 encephalopathy (LATE)

  • Agitation/aggression and behavioral and psychological symptoms of dementia (BPSD)

  • Postoperative delirium / perioperative neurocognitive disorders (elderly)

  • Delirium (hospitalized elderly)

  • Vascular dysfunction in AD / amyloid-related imaging abnormalities (ARIA)

  Other aging-related conditions

  • Sarcopenia / age-related muscle loss (including GLP-1–associated)

  • Obesity (older adults)

  • Menopause / menopausal symptoms

  • Falls and fall-related injuries

  • Pressure ulcers / pressure injuries (including in darkly pigmented skin)

  • Urinary/fecal incontinence (in dementia)

  • Hearing loss (with co-occurring memory concerns)

  • Osteoporosis / vertebral compression fractures

  • Knee osteoarthritis (total knee arthroplasty)

  • Chronic low back pain / chronic pain

  • Obstructive sleep apnea

  • Insomnia

  • Social isolation / loneliness

  • Dysphagia / upper-extremity mobility impairment (self-feeding)

  • Sepsis and ARDS (geriatric)

  • Systemic sclerosis-associated interstitial lung disease (SSc-ILD)

  • Anticholinergic drug-induced cognitive impairment / polypharmacy adverse events

  • Post-acute sequelae of COVID-19 (Long COVID) neurocognitive deficits

  • General biological aging (epigenetic/senescence biomarkers, healthspan)

  • Conditions monitored via digital biomarkers: UTIs, C. difficile infection, GI bleeding, dehydration, constipation, colorectal cancer

• National Institute on Alcohol Abuse and Alcoholism (NIAAA)

  Interest Areas:

  NIAAA-specific SBIR and STTR interests are tailored toward commercializing technologies that address the unique physiological, social, and clinical challenges of alcohol misuse.

  The NIAAA specifically encourages small business applications in the following high-priority areas:

  • Biosensors and Wearables: Developing non-invasive, wearable devices for real-time alcohol monitoring (e.g., transdermal sensors) that provide more accurate data than self-reporting for research and clinical use.

  • Digital Health and Telehealth: Creating mobile applications, AI-driven platforms, and software for the remote delivery of evidence-based treatments, such as Cognitive Behavioral Therapy (CBT) or recovery support services.

  • Pharmacotherapy Development: Advancing the discovery and testing of new medications to treat Alcohol Use Disorder (AUD), specifically focusing on those with commercial potential and lower side-effect profiles.

  • Diagnostic Tools and Biomarkers: Innovating point-of-care diagnostic tests and biological markers for early detection of alcohol-induced organ damage (liver, brain, heart) and Fetal Alcohol Spectrum Disorders (FASD).

  • Advanced Data Analytics: Utilizing machine learning and big data tools to analyze large health datasets to predict relapse, identify high-risk drinking patterns, or personalize treatment plans.

  • Regulatory Support: Utilizing the Commercialization Readiness Pilot (CRP) to fund late-stage R&D, such as IND-enabling studies, manufacturing scale-up, or clinical trial verification required for FDA clearance.

  • Behavioral Interventions: Developing tools designed to improve treatment adherence, reduce stigma, or provide prevention and therapies to treat alcohol use disorder

• National Institute of Allergy and Infectious Diseases (NIAID)

  Interest Areas:

  The NIAID Small Business portfolio supports product development and commercialization in the areas of: 

  • The immune system, microbe biology, and host-microbe interactions, 

  • Diagnostic and prevention strategies 

  • Treatment and cure strategies 

  Indications Of Interest:

  Bacterial infections / antimicrobial resistance

  • Tuberculosis (drug-susceptible, drug-resistant, and latent TB)

  • Nontuberculous mycobacterial pulmonary disease (M. abscessus, M. avium complex)

  • Pseudomonas aeruginosa infections (including in bronchiectasis)

  • Bronchiectasis (with chronic respiratory infection)

  • Sexually transmitted infections (including multidrug-resistant N. gonorrhoeae)

  • Recurrent bacterial vaginosis

  • Burn wound and skin/soft-tissue infections (multidrug-resistant)

  • Healthcare-associated infections / surface biofilms (incl. C. difficile, Candida auris)

  • Acinetobacter baumannii (carbapenem-resistant) infections

  • Klebsiella pneumoniae infections

  • Spontaneous bacterial peritonitis

  • Bloodstream infections

  • Surgical site / post-surgical infections (GI surgery)

  • Clostridioides difficile infection (including with IBD)

  • Cholera

  • Pertussis (whooping cough)

  • Q fever, leptospirosis

  • Secondary bacterial pneumonia (NTHi after influenza)

  Fungal infections

  • Invasive / drug-resistant fungal infections (Candida, C. auris, Aspergillus, Cryptococcus)

  • Invasive aspergillosis

  • Mucormycosis

  • Cutaneous fungal infections / ringworm (dermatophytes)

  • Onychomycosis

  • Pneumocystis (and other DHFR-target fungi)

  • Alcohol-associated hepatitis (fungal/Candida target)

  Viral infections

  • HIV (treatment, prevention, cure/reservoir)

  • SARS-CoV-2 / COVID-19

  • Influenza (seasonal and pandemic)

  • Respiratory syncytial virus (RSV)

  • Human metapneumovirus

  • Chronic hepatitis B (including HIV/HBV co-infection)

  • Hepatitis A

  • Cytomegalovirus (drug-resistant, in transplant)

  • Neonatal herpes simplex virus

  • High-risk human papillomavirus (cervical cancer prevention)

  • Marburg and Ebola virus disease

  • Dengue

  • Powassan virus

  • Prion diseases / transmissible spongiform encephalopathies (CJD)

  Parasitic / vector-borne

  • Malaria

  • Babesiosis

  • Cryptosporidiosis

  • (Mosquito control for dengue, yellow fever, Zika)

  Autoimmune / immune-mediated and allergic diseases

  • Systemic lupus erythematosus / lupus nephritis

  • Sjögren's syndrome

  • Immune thrombocytopenia (ITP)

  • Immune-mediated thrombotic thrombocytopenic purpura (iTTP)

  • Type 1 diabetes

  • Celiac disease

  • Alopecia areata / autoimmune skin diseases

  • Multiple sclerosis

  • Severe allergic asthma

  • Food allergy / peanut allergy

  • Chronic urticaria

  Immunodeficiency / cellular-therapy targets

  • Primary immunodeficiencies / inborn errors of immunity (incl. ADA-SCID, CARD11 gain-of-function)

  • Common variable immune deficiency (CVID)

  • Enzymopathies (e.g., Mucopolysaccharidosis type I / Hurler syndrome)

  • Transplant rejection and graft-versus-host disease (kidney transplant, HSCT)

  Other / cross-cutting

  • Acute radiation syndrome (gastrointestinal ARS)

  • Cyanide poisoning (antidote)

  • Acute respiratory distress syndrome (ARDS)

• National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

  Interest Areas:

  The NIAMS small business program supports research and development of products and services for prevention, diagnosis and treatment of rheumatic, musculoskeletal and skin diseases. The research topics include, but are not limited to, the following: 

  1. Rheumatic Diseases.  The NIAMS supports research on rheumatic and related diseases including rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), Lyme arthritis, viral arthritis, gout, calcium pyrophosphate deposition disease (CPDD), spondyloarthropathies, and systemic autoimmune diseases such as systemic lupus erythematosus (SLE), systemic scleroderma (SSc), and autoimmune myositis. 

  2. Musculoskeletal Diseases.  The musculoskeletal system is composed of the skeleton, the muscles, and connective tissues such as cartilage, tendon, and ligament. The NIAMS supports research aimed at improving the diagnosis, treatment, and prevention of diseases and injuries of the musculoskeletal system and its component tissues. The topics in this area include research on musculoskeletal diseases such as osteoporosis, osteoarthritis, muscular dystrophy, and osteogenesis imperfecta; tissue engineered products; orthopedic devices and implants; and sports medicine and fitness. 

  3. Skin Diseases. The NIAMS supports research on chronic inflammatory skin diseases such as psoriasis, rosacea, acnevulgaris, atopic dermatitis; autoimmune skin diseases such as pemphigus, vitiligo, and alopecia areata; skin repair and regeneration in treatment of chronic wounds and reducing scar formation; and skin cancer prevention such as products preventing skin cancer in early-stage development.

  Indications Of Interest:

  Muscle / muscular dystrophies

  • Duchenne muscular dystrophy / dystrophinopathies (including Becker)

  • Myotonic dystrophy type 1 (DM1)

  • Limb-girdle muscular dystrophy 2B (LGMD2B) / dysferlinopathies

  • Skeletal muscle loss/trauma (regenerative reconstruction)

  Joints / bone / orthopedic

  • Rheumatoid arthritis

  • Osteoarthritis (including knee OA)

  • Meniscal injuries / post-meniscectomy syndrome / post-traumatic osteoarthritis

  • Arthrofibrosis

  • Distal femoral / traumatic fractures (nonunion)

  • Revision total knee arthroplasty (implant longevity)

  • Diabetic Charcot foot / Charcot osteoarthropathy and osteomyelitis

  • Lumbar interbody fusion / degenerative spine

  • Limb loss / amputation (skeletal prosthesis attachment)

  • Chronic / neuropathic joint pain (RA-associated)

  Skin

  • Psoriasis

  • Acne vulgaris

  • Allergic contact dermatitis

  • Wound healing / surgical flap reconstruction

• National Institute of Biomedical Imaging and Bioengineering (NIBIB)

  Interest Areas:

  The NIBIB Small Business Program aims to translate cutting edge technologies into commercial products to address critical healthcare challenges. Through grants and contracts, the program supports the development of innovative biomedical technologies that improve human health. Areas of interest span biomedical imaging, medical devices, health informatics, diagnostic and therapeutic technologies, and related innovations at the intersection of biology and engineering. Projects should demonstrate strong commercial potential while addressing significant unmet clinical needs in biomedical imaging and bioengineering.

  Specific program guidance includes:

  • Technologies may be demonstrated using a specific indication or model system, but the core innovation must be broadly applicable without significant reengineering. 

  • Applications fall outside NIBIB's mission if the primary focus is

    • developing technologies to elucidate basic biological functions or disease mechanisms, or

    • applying and testing previously developed tools or technologies.

  • Per NOT-EB-21-005, NIBIB only supports early-stage clinical trials, i.e., feasibility, Phase I, first-in-human, safety, or other small clinical trials, that inform technology development. NIBIB will notsupport applications with efficacy, effectiveness, or a post-market concern as an outcome.

  • NIBIB may modify or decline funding applications for budgetary, administrative, or programmatic reasons. This includes reducing budgets, shortening award periods, or choosing not to fund applications.

  • Awardees are strongly encouraged to contact NIBIB's Small Business Team about the Concept to Clinic: Commercializing Innovation (C3i) Program, a mentored, entrepreneurial training course that provides innovators with essential business tools to assess the commercial viability and potential business opportunity for their product.

  Indications Of Interest:

  Traumatic internal hemorrhage / occult abdominal bleeding

  • CNS diseases requiring blood-brain-barrier crossing: Alzheimer's disease, Parkinson's disease, glioblastoma, brain metastases

  • Adverse pregnancy outcomes (fetal growth restriction, preeclampsia)

  • Otitis media (pediatric acute otitis media and otitis media with effusion)

  • Critical-illness / surgical organ-function monitoring (and catheter-associated bloodstream infections)

  • Spinal surgery complications (dura / nerve root injury)

  • Bone marrow / hematologic sampling adequacy (diagnostic)

  Note: Several awards (surgical suturing trainer, X-ray detectors, small-animal imager, antibody purification) are general-purpose tools or manufacturing platforms with no specific disease indication.

• Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

  Interest Areas:

  NICHD supports research that includes, but not limited to the following:

  • Reproductive health, including fertility, conception, contraception, and pregnancy

  • Health of women before, during, and after pregnancy, and fetal development and infant survival

  • Typical and atypical development and growth in children and adolescents, including experiences of trauma and critical illness 

  • Gynecologic health and disease; safe and effective therapeutics and devices for children and pregnant and lactating women; dynamics of human populations across the lifespan

  • Optimizing function in people with intellectual, developmental, and physical disabilities

  Indications Of Interest:

  Gynecologic / reproductive / contraception

  • Infertility (IVF, male infertility, tubal patency evaluation)

  • Endometriosis

  • Uterine fibroids (hysterectomy / myomectomy)

  • Vulvodynia / vestibulodynia and chronic pelvic pain

  • Pelvic floor disorders (vaginal stenosis, dyspareunia, vaginismus, vaginal atrophy)

  • Contraception (non-hormonal female, male, and multipurpose prevention against HIV/STIs)

  • Perimenopause / menopause

  • Vaginal cuff dehiscence (surgical complication)

  Maternal / pregnancy

  • Severe maternal morbidity and mortality

  • Maternal / postpartum hemorrhage

  • Preterm / impending labor prediction

  • Adverse pregnancy outcomes (fetal growth restriction, preeclampsia)

  • Labor induction/augmentation and postpartum uterine atony (oxytocin)

  Neonatal / pediatric

  • Preterm infant nutrition (NICU, total parenteral nutrition, human-milk fortification)

  • Necrotizing enterocolitis (NEC)

  • Pediatric injury prevention (side-impact head injury in child safety seats)

  Rare metabolic / genetic / neurodevelopmental disorders

  • Long-chain fatty acid oxidation disorders (LCFAODs)

  • Urea cycle disorders / hyperammonemia

  • Homocystinuria

  • Rare monogenic neurodevelopmental disorders

  Disability / rehabilitation

  • Limb loss / amputation (pediatric and adult prosthetics)

  • Spinal cord injury / tetraplegia

  • Traumatic brain injury / concussion and chronic brain injury

  • Stroke (upper-extremity rehabilitation)

  • Pediatric neuromuscular conditions (mobility / standing wheelchair)

  • Intellectual and developmental disabilities (IDD)

  Child development / behavioral / family

  • Child behavior problems / self-regulation and behavioral sleep problems

  • Effects of high-conflict divorce on children

  Other diagnostic targets

  • Muscle injury (rhabdomyolysis, muscular dystrophy), cardiac injury, and inflammatory myopathies (dermatomyositis, polymyositis) via CPK testing

• National Institute on Drug Abuse (NIDA)

  Interest Areas:

  Consistent with NIH and Presidential priorities, the NIDA Small Business Program supports research and development of innovative medical and non-medical products and services for substance use disorders (SUDs) and adverse health consequences related to non-disordered drug use. Proposed solutions should improve access, affordability, and coordinated care across prevention, diagnosis, treatment, and recovery. NIDA prioritizes scalable solutions deployable within integrated delivery networks across healthcare, criminal justice, workforce, education, housing, and social service systems. Specific areas include, but are not limited to:

  • Novel, mechanism-based treatments addressing the evolving overdose crisis (e.g., synthetic opioids, stimulants, polysubstance use)

  • Best-in-class opioid use disorder treatments that improve retention and outcomes for individuals not adequately served by existing medications

  • Innovative smoking cessation therapies that enhance adherence and long-term effectiveness

  • First-in-class pharmacotherapeutics and medical devices for stimulant and cannabis use disorders

  • Diagnostic tools for detection and quantification of drug exposure

  • Medical devices, including digital diagnostics and therapeutics, and clinical decision support systems supporting SUDs and comorbid mental health conditions, with particular attention to pediatric populations.

  • Digital health technologies addressing health-related social needs

  • Human-biology-based new approach methodologies and other commercial research tools

  • Forensic testing technologies identifying emerging drugs

  • FDA Drug Development Tools and Medical Device Development Tools

  NIDA strongly encourages applications that include early FDA engagement, consideration of regulatory pathways, payer engagement strategies, real-world evidence generation, and plans for sustainable adoption within integrated delivery networks and value-based care models.

  Indications Of Interest:

  • Opioid use disorder (OUD) — the dominant focus (medications, digital therapeutics, monitoring, diagnostics)

  • Substance use disorder (general / polysubstance)

  • Opioid overdose and opioid-induced respiratory depression

  • Opioid withdrawal syndrome

  • Cocaine use disorder

  • Methamphetamine / amphetamine / stimulant use disorder

  • Nicotine dependence / smoking cessation

  • Nicotine vaping dependence (vaping cessation)

  • Cannabis use (youth)

  • Anabolic androgenic steroid / performance-enhancing drug use

  • Xylazine intoxication (including fentanyl-xylazine)

  • Neonatal abstinence syndrome

  • Substance use disorder in co-occurring conditions (e.g., autism spectrum disorder, psychiatric comorbidity)

  Note: Many awards are fentanyl/xylazine detection tools, overdose-detection wearables, and digital therapeutics that all sit under the OUD/SUD umbrella above.

• National Institute on Deafness and other Communication Disorders (NIDCD)

  Interest Areas:

  NIDCD supports research including, but not limited to, the following:  

  • Novel technologies for studying, diagnosing, and treating hearing loss, tinnitus, or balance disorders.  

  • Novel diagnostic tools for testing human chemosensory function throughout the lifespan. 

  • Novel technologies for studying, diagnosing, and treating voice, speech, and language disorders such as laryngeal dystonia (spasmodic dysphonia), phonotrauma, stuttering, dysarthria, developmental language disorders, and aphasia.   

  • Innovative in vivo imaging capabilities that significantly advance visualization, diagnosis, and treatment of communication disorders in the clinic.  

  • Novel systems of augmentative and alternative communication (AAC) for individuals with motor speech impairment, including a brain-computer interface (BCI) prosthesis for communication. 

  • Novel assessments and interventions for late talking children or minimally verbal/ non-speaking individuals. 

  • Novel applications of machine learning / artificial intelligence algorithms in hearing aids, cochlear implants, AAC devices, or for the analysis of voice, speech, and language. 

  Indications Of Interest:

  • Hearing loss (sensorineural and severe-to-profound; cochlear implants and hearing aids)

  • Congenital / genetic hearing loss (e.g., TOMT- and otoferlin-linked)

  • Noise-induced hearing loss (occupational and recreational)

  • Age-related hearing loss / presbycusis

  • Tinnitus (including pulsatile tinnitus)

  • Otitis media with effusion (the leading cause of childhood hearing loss)

  • Newborn / pediatric hearing screening and diagnosis (auditory brainstem response)

  • Olfactory dysfunction / smell disorders

• National Institute of Dental and Craniofacial Research (NIDCR)

  Interest Areas:

  NIDCR supports small business–led development of technologies and products that translate dental, oral, and craniofacial (DOC) research into clinically actionable solutions across the lifespan. Emphasis is on feasibility, validation, regulatory readiness, and commercialization. Projects should align with NIDCR’s goal to rapidly translate oral health innovations toward clinical impact. Early engagement with program staff is encouraged to ensure alignment with mission and priorities. Scientific areas of interest include: 

  • Targeted DOC diagnostics and therapeutic platforms for tooth-related diseases and periodontal/peri-implant conditions

  • Orofacial pain assessment and management technologies, including clinical decision support

  • Oral microbiome-based diagnostics and therapeutic platforms for polymicrobial diseases

  • AI/ML-enabled predictive health and clinical decision support tools for DOC care

  • Advanced dental materials, restorative technologies, and digital manufacturing systems

  • Regenerative medicine technologies for craniofacial and dental tissue reconstruction

  • Immunomodulatory and precision therapeutic delivery systems for oral and craniofacial conditions

  • Digital behavioral and monitoring tools targeting DOC outcomes

  • Real-world evidence and patient outcome data platforms to support clinical adoption, evidence generation, and downstream coverage considerations

  • Implementation and dissemination technologies for priority-population oral health interventions

  • Integrated oral–systemic health assessment and intervention platforms

  • Regulatory and commercialization readiness tooling to support evidence generation, usability, and market adoption

  Indications Of Interest:

  • Dental caries / tooth decay (remineralization, caries arrest, diagnosis)

  • Periodontitis / periodontal disease (alveolar bone loss)

  • Xerostomia / dry mouth (radiation-induced, Sjögren's syndrome, medication-induced, age-related)

  • Radiation-induced oral and salivary gland fibrosis (head and neck cancer)

  • Oral cancer and oral lichenoid / premalignant lesions

  • Oropharyngeal squamous cell carcinoma (HPV-related)

  • Acute and subacute oral/dental pain (opioid-free analgesia)

  • Pulp and dentin damage from decay or trauma (regeneration / endodontics)

  • Tooth loss / dental implants (osseointegration and bone-quality assessment)

  • Oral and craniomaxillofacial bone defects (guided bone regeneration)

  • Craniomaxillofacial reconstruction (congenital, acquired, post-traumatic, and oncologic defects; nasal reconstruction)

  • Infant cranial malformations (e.g., plagiocephaly / craniosynostosis)

  • Obstructive sleep apnea (oral-cavity-based screening)

• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

  Interest Areas:

  NIDDK is interested in projects that include robust timelines for commercialization, requisite fundraising, and all required regulatory milestones.

  For those projects intended to support completion of research needed for an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or other regulatory clearance or approval, NIDDK is interested in projects that demonstrate how formal consultation with the U.S. Food and Drug Administration (FDA) has informed the research strategy.

  NIDDK is interested in Phase IIB and Commercialization Readiness Pilot projects that propose to continue the process of developing products that ultimately require clinical evaluation and approval by a Federal regulatory agency, and that position the projects for independence from NIH support after the project period. 

  Indications Of Interest:

  • Type 1 diabetes (monitoring, prevention/delay, bioartificial pancreas, therapeutic antibodies)

  • Type 2 diabetes / general diabetes management (continuous glucose and metabolic monitoring)

  • Obesity and associated metabolic disorders (insulin resistance, dyslipidemia, fatty liver disease)

  • Childhood nephrotic syndrome

  • Glycogen storage disease type 1b (with associated neutropenia and inflammatory bowel disease)

  • Lipodystrophy

  • Variceal bleeding / upper GI hemorrhage (in cirrhosis / portal hypertension)

• National Institute of Environmental Health Sciences (NIEHS)

  Interest Areas:

  NIEHS SBIR/STTR grants help small businesses transform cutting-edge research into developing innovative and commercially viable products such as tools, technologies, assays, or services to translate and communicate environmental health research into improvements in human health. NIEHS SBIR/STTR program uses a combination of research & development, technology transfer, and communication strategies to aid the mission of NIEHS. 
  The institute’s scientific areas of emphasis include, but are not limited to, the following: 
  •    Tools/technologies such as sensors, computational methods, and exposomics approaches  for detecting and assessing human exposures to environmental hazards 
  •    Innovative and/or alternative high-throughput or high-content assays/model systems,  computational toxicology approaches, and other related new approach methodologies (NAMs) for toxicity testing and understanding effects on human health and disease
  •    Tools/methods/applications for evaluating environmental health and safety of engineered nanomaterials and micro/nanoplastics
  •    Biomonitoring technologies   such as point-of-care approaches for personal exposure assessment and exposure mediated biological response biomarkers.
  •    Intervention technologies and precision environmental health approaches to prevent or reduce human exposures or adverse health effects related to environmental stressors
  •    Educational materials to promote or support understanding of environmental health science
  The NIEHS Superfund Research Program (accepting SBIR applications only) focused on detection and remediation technologies for hazardous substances with relevance to Superfund and/or other contaminated sites

  The NIEHS Worker Training Program (accepting SBIR applications only) also participates

  Indications Of Interest:

  • Obesity / metabolic disorders (endocrine-disrupting chemical exposure)

  • Organophosphate/carbamate pesticide toxicity (cholinergic neurotoxicity)

  • PFAS-related health effects (thyroid dysfunction, cancer, developmental toxicity)

  • Particulate matter / air pollution effects on cardiovascular and respiratory health

  • Heavy-metal exposure (arsenic, lead) from mining dust

  • Harmful algal bloom (eutrophication)-related health risks

  • Chemical genotoxicity / cancer risk (susceptibility in sensitive populations)

• National Institute of General Medical Sciences (NIGMS)

  Interest Areas:

  NIGMS supports the development of technologies to address complex and interdisciplinary research questions in i) basic research, ii) clinical areas that impact multiple organs systems and iii) biomedical workforce development/training through educational activities, that may require additional resources.

  Indications Of Interest:

  • Burn injuries and wounds (severity assessment; relevant to infection and hypertrophic scarring)

  Note: The other two awards are general-purpose technologies — long-acting peptide drug delivery (microencapsulation) and lipid-nanoparticle manufacturing for nucleic-acid delivery — with no specific disease indication.

• National Institute of Mental Health (NIMH)

  Interest Areas:

  To advance its mission, NIMH supports small businesses to develop technologies, including, but not limited to, the following: 

  • Neurotechnology development to enhance research on brain structure and function 

  • Central nervous system (CNS) drug discovery/development for treating mental disorders – novel drug screening assays, novel compounds and drug targets; Research & Development (R&D) ranging from compound synthesis up to early stage clinical trials 

  • Novel brain modulation methods/devices as potential therapeutics 

  • Biological markers for CNS dysregulation/function and mental illness - objective, measurable biological indicators of physiological or disease processes to further assess replicability, reproducibility, stability, etc. at the subject level 

  • Digital health technologies – as interventions or service delivery tools, to augment clinical care, and/or to enhance clinical research, and clinical trial design/implementation at the subject/patient level 

  • Technologies addressing basic, behavioral, and implementation science related to people living with HIV – including all areas listed above 

  Indications Of Interest:

  • Depression

  • Anxiety

  • Suicidal behavior / suicide risk and non-suicidal self-injury (including among juvenile-justice-involved youth)

  • Early childhood / child mental health problems (externalizing and internalizing symptoms)

• National Institute of Neurological Disorders and Stroke (NINDS)

  Interest Areas:

  NINDS utilizes the SBIR and STTR programs to enable the commercial development of tools and technologies that serve the NINDS mission space. Priority is given to proposals with the greatest potential to advance the NINDS mission. 

  NINDS is especially interested in the following, in no preferential order:

  1. Novel and innovative technologies that address significant unmet needs 

  2. Technologies in development for their first indication or initial market opportunity

  3. Technologies with a compelling need for federal support, such as those at a stage of development requiring de-risking to attract private investment, New Approach Methodologies (NAMs), and those addressing underserved markets including rare and pediatric disease indications

  4. Under-resourced technologies, indications, markets, and geographical regions within the NINDS SBIR/STTR portfolio and mission space

  5. New applicants pursuing their first SBIR/STTR-funded technology

  6. Applicants with a demonstrated track record of advancing technologies through commercialization milestones

  7. For continuation applications, applicants who have achieved intended outcomes under prior funding

  8. Applications demonstrating robust rigor in their approach and preliminary data

  Indications Of Interest:

  Neurodegenerative

  • Parkinson's disease (including deep brain stimulation programming)

  • Huntington's disease

  • Frontotemporal dementia / frontotemporal lobar degeneration

  • CLN1 Batten disease

  Cerebrovascular

  • Acute ischemic stroke (thrombolysis, cell therapy, and neurorehabilitation)

  Injury / trauma

  • Traumatic brain injury (recovery monitoring and therapeutics)

  • Spinal cord injury

  • Peripheral nerve injuries

  Seizure / pain / headache

  • Epilepsy (including treatment-resistant epilepsy)

  • Migraine (episodic and chronic)

  • Painful diabetic neuropathy / neuropathic pain

  Lysosomal storage / genetic

  • Mucopolysaccharidosis I (Hurler syndrome), IIIB, and IIIC

  Tumors / structural

  • Brain tumors (intraoperative surgical guidance)

  • Schwannoma / NF2-related schwannomatosis

  • Hydrocephalus (ventricular shunt monitoring)

  Note: A few awards are enabling neurosurgical/imaging tools (portable intraoperative MRI, real-time resting-state fMRI) applied broadly across brain disease rather than to a single indication.

• National Institute of Nursing Research (NINR)

  Interest Areas:

  Areas of interest include innovative small business proposals as they relate to NINR research priority areas of intervening on the conditions of daily life that influence health, using multilevel or multi-sectoral approaches to prevent chronic conditions and improve the outcomes of those with chronic conditions, promoting healthy school environments, meaningful engagement of communities at all stages of the research process, and integrating technological advancements, particularly in artificial intelligence (AI), to streamline and improve healthcare outcomes.

  Indications Of Interest:

  • Adolescent and young adult cancer (and febrile neutropenia as the key treatment complication)

  • Work-related musculoskeletal back injuries (occupational injury prevention among direct care workers)

• National Library of Medicine (NLM)

  Interest Areas:

  The NLM Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) program supports the development of biomedical informatics tools and methods which are best disseminated through commercialization.

  The program aims to encourage small businesses to develop innovative technologies, tools, methods, and software platforms that advance:

  • Trustworthy, reproducible, and rigorous biomedical AI

  • Biomedical data infrastructure at scale

  • Sustainable biomedical reference resources and platform science

  • Market innovative human-centered use and impact informed biomedical informatics tools and methods

  Applications which utilize, integrate, or build upon data, resources, and tools fostered by NLM and NIH supported communities are encouraged. 

  Indications Of Interest:

  • Obstructive lung disease (COPD and asthma) — detection and monitoring

• Office of Research Infrastructure Programs (ORIP)

  Interest Areas:

  ORIP supports research projects to develop technology including, but not limited to, the following: 

  • Create, characterize, or improve models of human disease; and develop new approach methodologies (NAMs) to complement or reduce the use of animal models in research. 

  • Preservation, revival and monitoring of cells, tissue, organs or gametes from model systems. 

  • Validate research models to enhance the rigor and reproducibility of pre-clinical studies. 

  • Devices and technologies required for development and maintenance of conventional and NAM biological model systems, including those for advancing the care, welfare, housing, and management of these models; or sensor and monitoring technologies for the surveillance of models or environmental factors that lead to improved rigor and reproducibility for studies using these models.

Are there any additional benefits I would receive?

Beyond the award itself, recipients gain:

• Government validation and credibility that builds investor and partner confidence.

• Enhanced visibility through NIH and HHS award announcements.

• Access to the federal innovation ecosystem, including potential collaboration with NIH labs and federal health programs.

• Stronger commercial and exit potential, since non-dilutive funding matures technology, de-risks commercialization, and increases attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Open Date (Earliest Submission Date): August 05, 2026.

Application Deadlines (all due by 5:00 PM local time of applicant organization):

• September 05, 2026

• January 05, 2027

• April 05, 2027

For the September 05, 2026 submission cycle:

• Scientific Merit Review: November 2026

• Advisory Council Review: January 2027

• Earliest Start Date: April 2027

For the January 05, 2027 submission cycle:

• Scientific Merit Review: March 2027

• Advisory Council Review: May 2027

• Earliest Start Date: July 2027

For the April 05, 2027 submission cycle:

• Scientific Merit Review: July 2027

• Advisory Council Review: August 2027

• Earliest Start Date: December 2027

The first application deadline is September 05, 2026 by 5:00 PM local time of applicant organization. No late applications will be accepted.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services through participating organizations including:

• National Institutes of Health (NIH)

• Centers for Disease Control and Prevention (CDC)

• U.S. Food and Drug Administration (FDA)

The SBIR program is a congressionally mandated program that supports commercialization of innovative technologies developed by U.S. small businesses. NIH, CDC, and FDA set aside a portion of their extramural research budgets to fund SBIR awards.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

The NOFO states that reviewers evaluate applications based on:

• Significance

• Investigator(s)

• Innovation

• Approach

• Environment

Strong applications are likely to:

• Address an important unmet health, scientific, or public health need

• Demonstrate strong scientific and technical merit

• Present a compelling commercialization opportunity

• Show a clear path toward product development and market adoption

• Align closely with the mission and priorities of the target NIH Institute, CDC Center, or FDA Center

• Be led by a qualified team with the expertise needed to execute the proposed work

For Phase II and Fast-Track applications, commercialization potential and market opportunity are specifically evaluated.

Are there any restrictions I should know about?

Key restrictions include:

• Only U.S. small businesses are eligible.

• Foreign organizations are not eligible.

• Applications involving foreign subawards or subcontracts will not be considered for funding.

• Clinical trials are not accepted by certain participating Institutes and Centers, including NIAMS, NIDCR, NCATS, ORIP, and all participating FDA Centers under this NOFO.

• Cost sharing is not required.

• Companies must satisfy applicable SBA performance benchmark requirements.

• Duplicate or highly overlapping applications are not permitted.

• Phase I projects generally require at least 67% of research effort to be performed by the small business.

• Phase II projects generally require at least 50% of research effort to be performed by the small business.

Additional national security, foreign relationship, and foreign ownership restrictions apply and may result in denial of award.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development.

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations.

• Identify the right IC and mechanism (Phase I, Phase II, Fast-Track, Phase IIB, or CRP) for your project's stage and clinical trial needs, and position your company for long-term growth.

Additional Resources

Review the solicitation here.

DOI & IARPA - EMERGING TECHNOLOGY ACCELERATOR (ETA) PROGRAM ANNOUNCEMENTDOI-ETA-FY26-30

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Emerging Technology Accelerator (ETA) Program Announcement (DOI-ETA-FY26-30) is a multi-program IARPA funding vehicle supporting high-risk, high-payoff R&D across multiple active programs (e.g., ARCADE, COSMIC, DECIPHER, LocUS). Awards are made as Prototype Other Transaction Agreements (OTs) through a competitive, white paper–first process.

There is no fixed submission deadline — White Papers per Program: Continuous, after the posting of Q&As (Preferred).

This is a rolling opportunity, but programs can close once sufficient white papers are received. That creates real urgency: if you are aligned, you should apply as soon as possible before a program is re-labeled “Not Active.”

How much funding would I receive?

Not specified in the solicitation.

• The Government will make multiple Prototype OT awards

• Funding depends on:

  • Quality of proposals

  • Availability of funds

• Awards may be:

  • Partial (only parts of proposals funded)

  • Incremental or phased

No award size ranges or total program value are provided.

Research Topics:

• 1. ARCADE – ARTIFICIAL REASONING FOR CIRCUIT AUTOMATION AND DESIGN ENGINEERING (FY26) - ACTIVE

  ARCADE transforms and accelerates electrical circuit design within the Intelligence Community (IC) by leveraging Artificial Intelligence (AI) to develop an intelligent, comprehensive AI-knowledge assistant that extracts key information from vast technical documentation and enables engineers to perform quick, intuitive queries to meet the speed of mission.

  The technical information ingested by ARCADE will include text, datasheets, diagrams, schematics, tables, and graphs. ARCADE extracts crucial details about electrical components, their specifications and interfaces to compile them into a comprehensive searchable knowledge platform.

  Going beyond a simple search engine, ARCADE aims to suggest and recommend optimal components based on design requirements, constraints, and performance parameters as specified through user-defined prompts. This capability enables engineers to perform swift, targeted queries, dramatically reducing the time it takes to find, compare, and select suitable parts. It also aims to help identify optimal components and potential alternatives more efficiently by providing comparison tables and explanations for why specific components were selected, effectively saving engineers from manually sifting through thousands of documents. Ultimately, ARCADE will lead to faster, more accurate, and more robust circuit designs, ensuring Government missions can be deployed with unprecedented speed and reliability.

• 2. COSMIC – COMMERCIAL OBSERVATION FOR SPATIO-TEMPORAL MONITORING FOR INDICATIONS OF CHANGE (FY26) - ACTIVE

  The aim of the Commercial Observation for Spatio-temporal Monitoring for Indications of Change (COSMIC) program is to formulate a methodology to leverage commercial remote sensing technologies and open source geolocated information to generate pseudo-persistent data (PPD). This will be done by combining and translating complex and novel data, such as nonnadir imagery and non-Red,Green, Blue (RGB) spectral bands, using Artificial Intelligence (AI) and computer vision-based methodologies into a layered, temporal geospatial model understandable by commercial agentic AI systems. COSMIC will enable the development of an agentic AI analytic system trained by commercial vendors and equipped to answer intelligence questions by bridging the gap between the Intelligence Community (IC) data characteristics and the simpler solutions offered by commercial vendors.

  COSMIC will foster routine updating and modelling of baseline geospatial information in areas through multi-source, persistent surveillance. New sensors will fluidly be incorporated into the generation of layered geospatial models as constellations and sources change over time. In addition to improving the temporal resolution of layered geospatial models, COSMIC also aims to reduce resource demands by streamlining the derivation of actionable intelligence from these models. By integrating commercial remote sensing data with existing geospatial information, the program aims to create a harmonized and up-to-date representation of the physical world that can be used by agentic processes to answer questions relevant to the IC.

• 3. DECIPHER - (FY26) - ACTIVE

  Analysts often struggle to understand specialized language (e.g., slang, jargon, technical terminology) in various situations where dictionary definitions are not readily available, such as:

  • Non-English research articles with novel technical concepts and terms

  • Communications using slang

  • Undefined acronyms used within limited contexts

  • Web forum posts using coded language to mask illicit activities

  In these and similar contexts, analysts dedicate significant effort to triaging content pertinent to their domain of interest and understanding the meaning of unknown or novel specialized terms used within that domain. Adding to this challenge, language can change quickly, and adversaries can rapidly adapt their language to evade detection.

  The Decipher program’s goal is to create capabilities to detect and define specialized language in diverse, multilingual text collections. In Decipher, “specialized language” refers to single or multiword expressions that are difficult to disambiguate (e.g., acronyms, terminology with multiple meanings), are used to deliberately obfuscate interpretation (e.g., coded language), or for which accurate translations or explanations are not readily available (e.g., emergent jargon or slang) to typical non-expert users. Decipher will flag and extract candidate specialized terms in a document or corpus and then will provide candidate plain language translation and annotation of specialized terms, including jargon, slang, and acronyms. The program will also develop technology to annotate text with relevant social and contextual factors, capturing nuanced meaning, as well as to detect concept drift by monitoring use of terminology as it evolves over time.

• 4. LocUS – LOCATION USING SOUND (FY26) - ACTIVE

  The LocUS program aims to create technology that automatically and accurately geolocates multimedia content by maximally leveraging audio and visual information. LocUS will improve the geolocation capabilities of the Intelligence Community (IC) considerably beyond imageryonly methods and thereby increase the volume of content that can be accurately geolocated. This program will increase analysts’ ability to rapidly and accurately determine where a video, image, or audio clip was collected in the absence of accurate metadata indicating location. Applications for national security include human trafficking interdiction, hostage recovery, localization of malign actors using social media or confiscated devices, and other intelligence and law enforcement use cases.

• 5. MOVES – MOVEMENT OBSERVATION AND VIDEO-BASED EVALUATION SYSTEM (FY26) - ACTIVE

  The intelligence community (IC) would benefit from the ability to diagnose, from open-source data, medical conditions in individuals and populations. This ability would enable, e.g., monitoring of the spread of health threats (disease, chemical accidents or attacks, environmental toxins, etc.) and other medical intelligence analyses. The MOVES program aims to demonstrate the feasibility of this long-term goal by addressing a subset of the challenges associated with generalized diagnosis from video.

  The MOVES program will focus on diagnoses of neurological conditions that typically affect people’s movement and demonstrate that it is feasible to diagnose such conditions from challenging input video that may:

  • Be taken from non-ideal angles

  • Include subjects wearing a wide variety of clothing styles

  • Show partially obstructed subjects

  The program requirements are selected to ensure a path to rapid adoption and trust in the algorithms’ performance by medical professionals. Key challenges include the nature of the videos as described above, especially finding movements that are diagnostic of conditions, differentiating between similar symptoms of different disorders, and providing enough information to the medical professionals about how the diagnosis was made so that they can verify the diagnosis and build confidence in the algorithm performance.

Are there any additional benefits I would receive?

Yes:

• Potential follow-on production Contract or OT if prototype is successful

• Direct engagement with IARPA and Intelligence Community stakeholders

• Access to Government-furnished data (program-dependent)

• Independent Test & Evaluation (T&E) feedback throughout development

What is the timeline to apply and when would I receive funding?

Application timeline:

• White Papers per Program: Continuous, after the posting of Q&As (Preferred)

• Full proposals: By invitation only

Process:

1. Submit White Paper

2. Government evaluates for viability

3. If selected → invited to submit full proposal

4. If selected → negotiation → award

Award timing:
Not specified in the solicitation.

Where does this funding come from?

• Department of the Interior (DOI), Interior Business Center (IBC)

• In partnership with IARPA (Intelligence Advanced Research Projects Activity)

Authority:

• Issued under 50 U.S.C. § 3024(m)(6) for Prototype OT agreements

Who is eligible to apply?

Eligible:

• All responsible sources capable of meeting requirements

• U.S.-based entities (prime must be U.S.)

• Teams including:

  • Small businesses

  • Non-traditional defense contractors (NDCs)

  • Non-profits

Foreign participation:

• Allowed only as part of a U.S.-based team

Not eligible:

• Government agencies

• FFRDCs

• UARCs

• Government-affiliated organizations with privileged access

What companies and projects are likely to win?

Based on evaluation criteria, winning proposals will:

• Demonstrate innovative, high-risk/high-payoff technical approaches

• Clearly align with specific program objectives

• Show feasible execution plans with defined milestones

• Include strong technical teams and capabilities

• Address technical risks with mitigation strategies

• Offer IP terms that allow Government transition

The Government prioritizes:

• Scientific merit

• Relevance to IARPA mission

• Resource realism

Are there any restrictions I should know about?

Yes — several important ones:

Submission restrictions

• One program per white paper

• Must follow strict formatting and page limits

Funding restrictions

• No facility construction

• No commercialization costs

Technical restrictions

• Classified proposals are not accepted

IP & data

• Government requires sufficient rights for transition

• Must disclose IP ownership and restrictions

Compliance requirements

• NSPM-33 research security disclosures required

• Potential foreign influence review and mitigation

How long will it take me to prepare an application?

Requirements include:

• White Paper (up to ~8 pages technical content)

• If invited:

  • Full technical proposal (≤15 pages)

  • Detailed cost proposal

  • Multiple compliance attachments

This is a moderate-to-high effort application, especially at full proposal stage.

How can BW&CO help?

BW&CO can support:

• Program selection (which ETA program to target)

• White paper strategy and positioning

• Technical narrative development aligned to IARPA evaluation criteria

• Full proposal development (if invited)

• IP, compliance, and structure alignment

• End-to-end submission management

Additional Resources

Review solicitation here.

ARPA-H - SBIR/STTR Broad Agency Announcement (BAA)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

This is the ARPA-H SBIR/STTR Broad Agency Announcement (BAA) for high-impact healthcare technologies across seven topic areas. It uses a two step application process (Solution Summary → Technical Presentation) and supports Phase I, Direct-to-Phase II, and Fast Track awards.

There is strong urgency to prepare early, but note:

• The Solution Summary Due: July 10, 2026 (11:59PM ET)

• The solicitation is currently a draft and not yet accepting applications

Because ARPA-H uses a gated, competitive process with strict technical novelty requirements, companies should begin positioning immediately—especially given topic-specific windows and evolving amendments.

How much funding would I receive?

Funding depends on phase and topic. Typical amounts are:

• Phase I: up to $600,000

• Phase II: up to $3,500,000

Some topics specify:

• ~$600k (Phase I) and $3.5M (Phase II) (Topics 1–4, 7)

• $3.5M (Phase II only) (Topics 5–6)

All awards are issued as Firm-Fixed-Price (FFP) contracts with milestone-based payments

Research Topics:

• ARPA-H 01 - Development of an annual test to inform women about their future fertility

  The purpose of this topic is to discover new biomarkers that provide women with actionable data for fertility planning.  Results from this work will help inform the program manager regarding the feasibility of future programs focused on enhancing natural fertility before the need of IVF and guiding the development of women’s health monitoring and improvement tools. This work will develop a diagnostic test that can assess fertility status and generate an estimated timeline for the onset of infertility. This topic seeks to develop a test that is affordable, suitable for at least annual use, and provides user-friendly results for patients and care teams to support childbearing decisions.   

• ARPA-H 02 - Versatile Bioadhesives

  The purpose of this topic is to develop surgical glues with antimicrobial properties to combat infections due to surgery. In addition, the novel multifunctional surgical glue will also have desired properties such as controllable reversibility and degradability and be tissue/organ agnostic to stop bleeding with unknown sources. Overall, successful completion of this SBIR project will not only support the clinical implementation of bioprinted organs but also provide novel solutions to tackle unmet clinical needs in managing surgical leaks and infections and reduce overall medical costs.   

• ARPA-H 03 - Universal Platform for Living Adaptive Toxin-removal (UNI-PLAT)

  The purpose of this topic area is to catalyze the development of a universal, “plug-and-play” synthetic biology platform that enables next-generation microbial chassis capable of performing a broad array of programmable functions. While this solicitation primarily uses toxin removal as a proof-of-concept in relation to chronic disease management, the platform is intended to be adaptable to a range of challenges across industries such as environmental remediation, biomanufacturing, agriculture, holistic medicine, and therapeutic discovery. The broader goal is to create a stable, reliable, and easily reprogrammable microbial platform that demonstrates potential for cross-sector impact beyond the initial use case. 

• ARPA-H 04 - Breaking Ground: The First Curative, Non-Invasive, Long-Lasting Therapy for Endometriosis

  The purpose of this topic aims to advance progress in the endometriosis field by identifying and commercializing non-invasive therapeutics that address the root cause of the disease. Proposers are expected to develop a first-of-its-kind, non-invasive therapy capable of reducing the size of endometriosis lesions, deactivating endometriosis tissue, and/or preventing regrowth thereby ideally achieving curative outcomes. Additionally, proposers need to showcase a solution that has precise, targeted specificity, ensuring the treatment accurately locates and addresses endometriosis lesions without causing adverse effects elsewhere in the body.

• ARPA-H 05 - ARPA-H Lineage Topic

  The purpose of this topic supports the advancement, commercialization, and translation of technologies that originated from ARPA-H funded efforts. It is intended to help small businesses and startups develop viable products based on these technologies. ARPA-H’s goal is to give small businesses an off-ramp to finish developing their technology/product, explore secondary or interim applications of the technology, and time to achieve self-sufficiency.

• ARPA-H 06 - Rapid Comprehensive Diagnostic Test for Multi-System Autoimmune Disease

  The overall purpose of this topic is to spur the development of novel, rapid diagnostic assays for multi-system autoimmune disease, which represents an unmet healthcare need. Moreover, in its ideal embodiment this diagnostic test might allow typical primary care physicians to diagnose and predict tissue-specific autoimmune disease manifestations, thereby streamlining referral of the patient to a specialist. This goal is made more feasible by recent technological developments incility to detect tissue-specific signatures of immune-mediated stress by assessing circulating cells and/or tissue-specific molecular products.  

• ARPA-H 07 - Virtual Human Brain for the Development of Neurosurgical Robotics

  The overall purpose of this topic aims to take a first step toward AI-assisted intracranial microsurgery, which will ameliorate patient outcomes as described in point 5 above, by creating a high-resolution, physically and anatomically accurate virtual human brain.

Are there any additional benefits I would receive?

Yes. ARPA-H provides hands-on commercialization support, including:

• Entrepreneur-in-Residence (EIR) program (strategic guidance on IP, regulatory, market strategy)

• Regulatory and reimbursement support

• Customer discovery and stakeholder introductions

• I-Corps program participation (optional)

• Potential Technical and Business Assistance (TABA) funding

Support is not guaranteed and is provided at ARPA-H’s discretion

What is the timeline to apply and when would I receive funding?

Key Dates

• Solution Summary Due: July 10, 2026 (11:59PM ET)

• Technical Presentation (if invited): September 9, 2026 (11:59PM ET)

Process Timeline

• Stage 1: Submit Solution Summary (4–6 pages)

• Stage 2: If invited → Technical Presentation + full materials

• ARPA-H response:

  • ~90 days after topic close for Stage 1 decision

  • ~30 days after presentation for final decision

• Awards targeted within ~180 days of topic closing

Funding Timing

• Payments are quarterly milestone-based, not upfront

Where does this funding come from?

Funding comes from:

• Advanced Research Projects Agency for Health (ARPA-H)

• Under the SBIR/STTR program, authorized by the U.S. Small Business Act

• Within the U.S. Department of Health and Human Services (HHS)

The program is designed to fund transformational health technologies with commercialization potential

Who is eligible to apply?

Core Eligibility

You must be a Small Business Concern (SBC) that:

• Has ≤500 employees

• Is majority U.S.-owned

• Performs work in the United States

SBIR Requirements

• PI >50% employed by small business

• Work share:

  • Phase I: ≥66% by small business

  • Phase II: ≥50% by small business

STTR Requirements

• Must include a research institution partner

• Work share:

  • ≥40% small business

  • ≥30% research institution

Additional Requirements

• SAM.gov registration

• SBA Company Registry

• Foreign affiliation disclosures

• Required certifications at submission

What companies and projects are likely to win?

ARPA-H is explicitly looking for:

• Non-incremental, breakthrough technologies

• Solutions with clear technical novelty and feasibility

• Teams with:

  • Proven ability to execute

  • Commercialization capability

• Projects that:

  • Address major unmet health needs

  • Have a credible path to market and impact

  • Can reach a commercial inflection point

Strong proposals demonstrate:

• Clear technical milestones and risk mitigation

• Evidence-backed claims

• A viable commercialization plan

Incremental or purely academic work is unlikely to be competitive

Are there any restrictions I should know about?

Key restrictions include:

• No incremental R&D—must be transformative

• No Phase III proposals

• Must follow topic-specific eligibility (phase/type)

• Strict foreign affiliation disclosure and national security review

• Funding may be denied for:

  • Security risks

  • Undisclosed foreign relationships

• Proposal cap: max 6 submissions per fiscal year across HHS

Other constraints:

• Must submit through ARPA-H Solutions site only

• No email or paper submissions accepted

How long will it take me to prepare an application?

Typical effort:

• Stage 1 (Solution Summary):

  • 4–6 pages

  • ~1–3 weeks for a prepared team

• Stage 2 (if invited):

  • Full technical package + presentation

  • ~3–6+ weeks

Additional prep time may be required for:

• Registrations (SAM can take >14 business days)

• Certifications and compliance documentation

How can BW&CO help?

BW&CO can support across the full lifecycle:

• Topic selection and win strategy positioning

• Translating your technology into ARPA-H-aligned narratives

• Writing:

  • Solution Summary

  • Technical presentation materials

• Building commercialization strategy aligned to ARPA-H expectations

• Preparing for technical Q&A and evaluation criteria

• Managing compliance and submission requirements

Additional Resources

Review solicitation here.

Arcane Thunder 27 (AT 27)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

This is an RFI (Request for Information), not a funding opportunity, but it is a critical gateway to Army experimentation and potential follow-on contracting. The U.S. Army is seeking cutting-edge technologies for Arcane Thunder 27 (AT27), a major multi-domain experimentation campaign.

If selected, your technology may be invited to participate in field demonstrations and exercises with operational units. This is a high-visibility pathway to engage directly with the Warfighter and DoD stakeholders.

Submission deadline: 22 May 2026 : 22:59 CDT.
Missing this deadline means waiting for future cycles—there is no guarantee of a re-open.

How much funding would I receive?

This RFI does not include funding, but funding would shortly follow.

What could I use the funding for?

AI-Enabled Command & Control

• Edge-deployed AI for decision support, wargaming, and risk analysis

• Automated synchronization across units and systems

• AI models that operate in degraded or denied environments

Cyber, Electronic Warfare & Information Operations

• RF, cyber, and information effects (detect, disrupt, deceive)

• AI-driven emitter identification and behavior modeling

• Integrated cyber/EW payloads across platforms

Multi-Domain Sensing & Targeting

• Sensor fusion across RF, EO/IR, SAR, and other modalities

• Real-time targeting and geolocation (TDOA/FDOA/DF)

• Adaptive sensor tasking and AI-enabled targeting

Resilient Communications & Networking

• Low probability of intercept/detection (LPI/LPD) communications

• Self-healing mesh networks across air, ground, and space

• Cross-domain data transfer (unclassified to higher classification)

Autonomy, Robotics & Swarming

• Multi-platform control with single operator

• Adaptive swarm behavior based on mission and threat

• Autonomous detection, tracking, and targeting

Additive Manufacturing & Edge Modularity

• Field-ready 3D printing for parts and payloads

• Modular, plug-and-play payload architectures

• In-theater reconfiguration and resupply

Operational Simulation & Decision Tools

• Live, Virtual, Constructive (LVC) environments

• Digital twins and mission rehearsal tools

• End-to-end visualization of sensor-to-shooter workflows

Supporting Capability Areas

• Counter-UAS systems

• Space-based communications and sensing

• Defensive cyber operations

• Signature reduction (RF, visual, EMS)

• Threat replication and red-teaming tools

Are there any additional benefits I would receive?

Yes—this opportunity is about access and validation, not capital:

• Invitation to Army-led field experiments and demonstrations

• Direct engagement with:

  • Warfighters

  • DoD R&D organizations

  • Combatant Commands and other agencies

• Real-world testing in contested, denied, and austere environments

• Opportunity for follow-on contracting actions

• Visibility into how your product performs in multi-domain operations

What is the timeline to apply and when would I receive funding?

Submission deadline: 22 May 2026 : 22:59 CDT.

Key milestones:

• NLT 30 September 2026: Down-select notifications

• Late 2026: Planning conferences and interviews

• Early 2027: Final planning and risk reduction

• Apr – Jun 2027: Field exercises (CONUS and OCONUS)

• Funding timeline: Not specified in the solicitation.

Where does this funding come from?

• Not applicable.

• Issued by the U.S. Army DEVCOM C5ISR Center for experimentation purposes.

Who is eligible to apply?

• Industry

• Academia

• Individuals

• Laboratories

Must:

• Submit via Vulcan-SOF

• Provide a Scout Card + Technology Quad Chart

• Keep all submissions unclassified

What companies and projects are likely to win?

Selections favor technologies that are:

• Relevant to current military missions

• Technically mature and deployable

• Adaptable across multiple use cases

• Aligned to multi-domain operations

Are there any restrictions I should know about?

• Do NOT submit proposals — only Scout Cards

• No classified information allowed

• Must disclose ITAR/EAR/OFAC restrictions

• Data generated becomes U.S. Government property

• Must use required formats or risk rejection

How long will it take me to prepare an application?

Expect to prepare:

• Scout Card (per technology)

• Quad Chart

• Technical specs (SWaP, power, spectrum, etc.)

How can BW&CO help?

BW&CO can support across all phases of this CSO:

• Refine your positioning against Army priority areas

• Translate your tech into a high-impact Scout Card

• Ensure compliance with submission and formatting rules

• Increase likelihood of selection for demonstration

Additional Resources

Review solicitation here.

United States Transportation Command (USTRANSCOM) - Commercial Solutions Opening (CSO) - HTC71126SCSO1

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The United States Transportation Command (USTRANSCOM) Commercial Solutions Opening (CSO) (Solicitation Number: HTC71126SCSO1) is a continuously open funding pathway for companies developing commercial technologies that support global mobility, logistics, IT, and cybersecurity missions. Unlike traditional grants, this is a flexible acquisition vehicle that can lead directly to contracts or Other Transaction (OT) agreements.

This opportunity is continuously open until 1 February 2036 , with new Areas of Interest (AoIs) released on a rolling basis—some with dedicated funding and defined submission windows. If your solution aligns with USTRANSCOM’s mission, you can submit at any time, but Specific AoIs may have limited windows and should be monitored closely on SAM.gov.

How much funding would I receive?

Funding typically ranges from $500k to $5m.

What could I use the funding for?

1. AoI-901: Information Technology (IT) and Cybersecurity Solutions:

USTRANSCOM seeks IT and cybersecurity solutions that provide unique capabilities or more efficient approaches not currently in use by USTRANSCOM. These solutions should modernize enterprise systems, enhance operational efficiency, and strengthen security posture while meeting stringent security standards to support global integrated mobility operations.

Representative examples include:

• Cloud-based IT services and architecture

• Cybersecurity defense and threat detection systems

• Transportation management systems

• Artificial intelligence and machine learning applications

1.1. Security and Compliance Requirements:

All IT solutions must address: compliance with Defense Federal Acquisition Regulation Supplement (DFARS) 252.204-7012 for unclassified systems, adherence to National Industrial Security Program Operating Manual (32 CFR Part 117) for classified systems, implementation of Risk Management Framework processes, support for Authority to Operate requirements, and incident reporting capabilities per USTRANSCOM requirements.

1.2. Technical Data and Software Rights:

Offerors must identify any intellectual property, data rights restrictions, and licensing requirements associated with their proposed solutions. Submissions should clearly outline how technical data and software rights will be managed to ensure compatibility with USTRANSCOM systems and compliance with applicable regulations.

2. AoI-902: Transportation and Logistics Optimization:

USTRANSCOM seeks solutions that optimize transportation and logistics operations, improve supply chain resilience, and enhance global distribution capabilities. Submissions should offer unique approaches or efficiencies not currently utilized by USTRANSCOM to address operational challenges, visibility, and scalability in support of the global mobility mission.

Representative examples include:

• Supply chain resilience and risk management

• Real-time tracking and visibility platforms

• Predictive analytics for logistics decision support

• Automated transportation and cargo handling systems

Are there any additional benefits I would receive?

• Access to FAR-based contracts or OT Agreements for Prototype Projects

• Ability to work directly with USTRANSCOM on mission-critical challenges

• Streamlined acquisition under DFARS Subpart 212.70

• Potential for multiple awards or follow-on opportunities

No additional non-monetary benefits are explicitly specified beyond contracting pathways.

What is the timeline to apply and when would I receive funding?

• CSO open period: continuously open until 1 February 2036

• General AoIs:

  • Submissions accepted at any time

  • No guaranteed response timeline

• Specific AoIs:

  • Posted on SAM.gov with defined submission windows

  • Timelines vary by AoI

Process timeline (not fixed):

1. Phase 1 – Solution Brief submission

2. Phase 2 – Presentation/Pitch (if invited)

3. Phase 3 – Full Proposal (if invited)

4. Award decision

Timing for award decisions and funding is not specified in the solicitation.

Where does this funding come from?

Funding comes from the United States Transportation Command (USTRANSCOM), part of the Department of War (DoW) .

Awards are executed under:

• Federal Acquisition Regulation (FAR) Part 12 contracts

• 10 U.S.C. 4022 Other Transaction (OT) authority

Who is eligible to apply?

Eligibility requirements explicitly include:

• Must provide commercial products, technologies, or services

• Must be a registered entity in SAM.gov to receive an award

What companies and projects are likely to win?

USTRANSCOM evaluates submissions based on:

• Alignment to mission needs

• Technical feasibility

• Innovation and uniqueness

• Milestone schedule realism

• Prior experience delivering similar solutions

• Affordability and return on investment

Projects most likely to advance:

• Demonstrate working capability (not conceptual only)

• Provide clear value over existing systems

• Show credible delivery plans and pricing

• Align directly with AoIs such as IT/cybersecurity or logistics optimization

Are there any restrictions I should know about?

Key restrictions include:

• Strict submission format requirements (e.g., Scout Card + video for General AoIs)

• Video must be ≤ 5 minutes and demonstrate working capability

• Non-compliant submissions will not be evaluated

• Submission costs are not reimbursed unless explicitly stated

• Must comply with:

  • DFARS cybersecurity requirements

  • National Industrial Security Program (for classified systems)

  • Risk Management Framework and Authority to Operate processes

How long will it take me to prepare an application?

Not explicitly specified, but based on requirements:

• Phase 1 includes:

  • Scout Card submission

  • 5-minute demo video OR up to 6-page white paper (for Specific AoIs)

Preparation time will vary depending on:

• Readiness of a working prototype

• Ability to produce a demonstration video

• Pricing and delivery estimates

How can BW&CO help?

BW&CO can support across all phases of this CSO:

• Identify the right AoIs and timing strategy

• Develop high-impact Solution Briefs and demo narratives

• Structure submissions to align with evaluation criteria

• Prepare Phase 2 pitches and Phase 3 proposals

• Ensure compliance with format, pricing, and technical requirements

Additional Resources

Review solicitation here.

xTech|Phantum Competition (ARM26BX01-NP003)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The U.S. Army is seeking small businesses developing quantum sensors and photonics technologies through the xTech|Phantum Competition. This is a gated pathway to SBIR funding—only competition winners can submit a Phase I proposal. Companies can earn prize money, engage directly with the Department of War, and position themselves for follow-on SBIR funding.

White paper submission deadline: May 6, 2026

How much funding would I receive?

• Phase I SBIR:

  • Up to $300,000

  • 6-month period of performance

• Prize money:

  • Not specified in the solicitation

What could I use the funding for?

Phase I funding is for feasibility and concept development, including:

• Demonstrating technical advantage over existing solutions

• Developing concept plans aligned with Army modernization priorities

• Providing supporting technical literature and performance data

• Building a commercialization strategy (defense and commercial markets)

• Creating a technology development roadmap

• Delivering a concept demonstration at the end of Phase I

Technology focus areas include:

• Quantum sensors and quantum clocks for non-GPS PNT

• Quantum RF sensors

• Quantum electromagnetic sensors

• Photonics for communications and edge processing

Are there any additional benefits I would receive?

• Direct engagement with the Department of War (DoW)

• Feedback from Army stakeholders to accelerate technology development

• Entry into the Army’s Science & Technology ecosystem

• Eligibility to submit a Phase I SBIR proposal (only if selected as a winner)

What is the timeline to apply and when would I receive funding?

• White paper submission deadline: May 6, 2026

• xTech|Phantum competition selection timeline: Not specified

• Phase I SBIR award timing: Not specified

• Phase I performance period: 6 months

Where does this funding come from?

• Assistant Secretary of the Army for Acquisition, Logistics and Technology (ASA(ALT))

• U.S. Army Directorate for Strategy & Transformation (DAMI-ST)

• Delivered via the xTech|Phantum Competition and Army SBIR program

Who is eligible to apply?

• Must participate in the xTech|Phantum competition

• Only competition winners are eligible to submit a Phase I SBIR proposal

Additional eligibility requirements are not specified in the provided document.

What companies and projects are likely to win?

The Army is prioritizing companies developing:

• Quantum technologies enabling non-GPS positioning, navigation, and timing

• Quantum RF sensors with improved sensitivity, bandwidth, and SWaP

• Electromagnetic sensors detecting low-power or non-RF signals

• Photonics systems for secure, high-speed communications and edge computing

Strong applications will:

• Demonstrate clear technical feasibility and differentiation

• Show dual-use commercial potential

• Align directly with Army modernization priorities

• Provide credible pathways to prototype and field deployment

Are there any restrictions I should know about?

• Only xTech|Phantum competition winners can submit a Phase I SBIR proposal

• Proposals from non-participants or non-winners will not be evaluated

• CMMC requirement: Level 1

Other restrictions (e.g., cost share, ownership constraints) are not specified.

How long will it take me to prepare an application?

• Not specified in the solicitation

• Application requires submission of a white paper by May 6, 2026

How can BW&CO help?

BW&CO can support across both stages of this opportunity:

• xTech white paper strategy and drafting

• Positioning your technology against Army priorities

• Translating commercial tech into defense use cases

• Preparing a competitive Phase I SBIR proposal (if selected)

• Building commercialization and transition plans aligned with Army expectations

Additional Resources

Review solicitation here.

Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Chemical or Radiation/Nuclear (CRN) Threats

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

This NIH opportunity (RFA-AI-27-014) supports the development of medical countermeasures (MCMs) and enabling technologies to address chemical and radiation/nuclear (CRN) threats in civilian settings. The program is administered by NIAID through the Radiation and Nuclear Countermeasures Program (RNCP) and Chemical Countermeasures Research Program (CCRP). It is designed to fund early and preclinical work that can diagnose, mitigate, or treat injuries following exposure.

This is a forecasted opportunity with an Estimated Application Due Date: October 9, 2026. Founders working in radiological, nuclear, or chemical threat preparedness should begin positioning now, as this is a complex NIH cooperative agreement with long lead times.

How much funding would I receive?

Funding amounts are not specified in the solicitation, but we anticipate funding to range from $500k - $2m.

What could I use the funding for?

Funding supports research and development of medical countermeasures and enabling technologies addressing CRN threats, including:

Radiation and Nuclear Countermeasures Program (RNCP):

• Radiation-focused models

• Biomarkers of radiation damage

• Devices to assess and predict injury

• Products to improve survival and reduce morbidity across organ systems

Chemical Countermeasures Research Program (CCRP):

• Preclinical development of products

• Technologies to mitigate or treat injury after exposure to Chemicals of Concern

• Solutions designed for post-exposure, civilian mass casualty settings

All work must align with developing capabilities to diagnose, mitigate, or treat acute and delayed effects of radiation or chemical exposure during or after public health emergencies.

Are there any additional benefits I would receive?

• Not specified in the solicitation.

What is the timeline to apply and when would I receive funding?

• Estimated Post Date: July 10, 2026

• Estimated Application Due Date: October 9, 2026

• Estimated Award Date: July 1, 2027

• Estimated Project Start Date: July 1, 2027

Additional timeline details are not specified in the solicitation.

Where does this funding come from?

This funding is provided by the National Institute of Allergy and Infectious Diseases (NIAID) on behalf of the NIH.

It is authorized under:

• Sections 301 and 405 of the Public Health Service Act (42 USC 241 and 284)

• Federal Regulations: 42 CFR Part 52 and 2 CFR Part 200

The program is supported by a congressional mandate (Public Law 109-149, Dec. 30, 2005) to advance research addressing chemical and radiological threats.

Who is eligible to apply?

For-profit:

• Small businesses

• For-profit organizations other than small businesses

What companies and projects are likely to win?

Projects that align closely with the stated program goals, including:

• Development of medical countermeasures for radiation or chemical exposure

• Technologies addressing post-exposure treatment in civilian mass casualty scenarios

• Preclinical-stage innovations with clear pathways to mitigating injury or improving survival

• Tools for diagnostics, biomarkers, or injury assessment

Further selection criteria are not specified in the solicitation.

Are there any restrictions I should know about?

• Funding instrument is a cooperative agreement

• No cost sharing or matching requirement

Additional restrictions are not specified in the solicitation.

How long will it take me to prepare an application?

Given this is an NIH cooperative agreement focused on preclinical and translational research, preparation timelines are typically substantial, but exact expectations are not specified in the solicitation.

How can BW&CO help?

BW&CO can support:

• Translating your technology into NIH-aligned positioning

• Mapping your solution to RNCP or CCRP priorities

• Structuring a competitive preclinical development narrative

• Managing the full application process ahead of the October 9, 2026 deadline

Additional Resources

Review solicitation here.

AFRL - Multi-Spectrum Defensive Electronic Warfare (MSDEW) Advanced Research Announcement (ARA)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

This is a rolling Air Force Research Laboratory (AFRL) Advanced Research Announcement (ARA) for the Multi-Spectrum Defensive Electronic Warfare (MSDEW) program. It does not accept proposals directly—you must apply through future “calls” released under this ARA.

The ARA remains open for calls until 13 JULY 2027. Each call will define its own requirements, funding, and deadlines. If you are building advanced electronic warfare, sensor fusion, or multi-domain defense technologies, this is a long-running, high-budget entry point into AFRL funding—but you must actively monitor and respond to individual calls as they are released.

How much funding would I receive?

• Total program value: $396,600,000.00

• Typical award size:

  • $20,000,000.00 to $100,000,000.00 per award

• Number of awards:

  • Multiple awards expected

  • No limit per offeror

• The Air Force reserves the right to exceed these amounts if in its best interest

What could I use the funding for?

Funding supports R&D and prototyping in multi-spectrum electronic warfare systems, including:

• Sensor development across RF and electro-optical domains

• Threat warning and countermeasure systems

• Integration of multi-sensor systems across air, space, and cyber

• Modeling, simulation, and analysis (MS&A)

• Testing, experimentation, and demonstration (including flight tests)

• Software development (signal processing, algorithms, interfaces)

• System architecture (open systems, integration frameworks)

• Transitioning technologies to operational systems

Core technical areas include:

• Electro-optic & multi-spectrum countermeasures

• Directed energy threat warning

• Missile warning systems

• Cyber-secure and open EW systems

Are there any additional benefits I would receive?

• Potential access to large-scale DoD test environments, including flight testing

• Opportunity to transition technologies into Air Force operational systems

• Flexible award structures:

  • FAR-based contracts

  • Other Transactions (OTs)

• Ongoing opportunity to compete for multiple awards over several years

What is the timeline to apply and when would I receive funding?

• ARA open through: 13 JULY 2027

• Proposal deadlines:

  • To be determined (TBD) on individual calls

• Award timing:

  • TBD per individual call

  • Notification typically ~30 days after proposal submission

• Period of performance:

  • TBD per individual call
    

Where does this funding come from?

• Air Force Research Laboratory (AFRL), Sensors Directorate (AFRL/RYW)

• Funding supports U.S. national defense and electronic warfare capability development

Who is eligible to apply?

• Unrestricted solicitation

• Eligible applicants:

  • Businesses of all sizes

  • Educational institutions

• No cost sharing required

Additional notes:

• FFRDCs subject to eligibility determinations

• Foreign participation:

  • Not anticipated but may be allowed case-by-case

• No limit on number of proposals per offeror

What companies and projects are likely to win?

Proposals are evaluated primarily on:

Technical Merit (highest priority):

• Clear understanding of the problem

• Strong, feasible technical approach

• Relevant experience and qualified team

• Ability to advance the state of the art

• Potential to transition to operational use

Cost/Price (secondary):

• Realistic and justified cost structure

Projects that are most competitive will:

• Integrate multiple sensing modalities

• Demonstrate real-world applicability (lab + field/flight testing)

• Align with Air Force mission needs

• Enable transition to future defense systems

Are there any restrictions I should know about?

• Many awards will require Top Secret security capabilities

• Export control (ITAR/EAR) may apply

• Data rights heavily favor the Government (including unlimited rights for government-funded work)

• Strict proposal formatting and submission requirements

• Accounting system requirements for cost-reimbursement contracts

• Compliance with:

  • OPSEC

  • Program Protection Plan (PPP)

  • Safety regulations

• Foreign involvement may be restricted per call

How long will it take me to prepare an application?

• Not specified in the solicitation

However:

• Proposals are submitted in response to individual calls

• Each call will define:

  • Page limits

  • Technical and cost requirements

• Submissions include both technical/management and cost/business volumes

How can BW&CO help?

BW&CO can support you across the full lifecycle of this ARA:

• Monitor and identify relevant MSDEW calls

• Position your technology against AFRL priorities

• Develop compliant technical and cost proposals

• Structure OT vs FAR contract strategy

• Build transition narratives aligned to Air Force needs

• Manage complex submission requirements and timelines

How much would BW&CO Charge?

Our services range from an hourly engagement at $250 an hour to a full service at $15,000 + 5%.

Additional Resources

Review solicitation here.

NAVAL AIR WARFARE CENTER AIRCRAFT DIVISIONAIR SYSTEMS GROUP, PROPULSION & POWER ENGINEERING BAA

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

This is a Fiscal Year 2026 Broad Agency Announcement (BAA) from the Naval Air Warfare Center Aircraft Division (NAWCAD) focused on propulsion and power technologies for future Naval aircraft. It is a rolling opportunity covering multiple technical areas (BAA 121–125) with a continuous submission window until 30 September 2026.

The Navy is actively seeking white papers and proposals across electrical power systems, fuels and lubricants, operational energy, maintenance/health monitoring, and propulsion systems. Awards are made on a rolling basis, and funding availability is uncertain—so early engagement is critical.

How much funding would I receive?

Number of Awards: Multiple awards anticipated

• Estimated: $500K to $5 million. Award Size: Not predetermined; varies based on technical merit, relevance, and available funding

• Period of Performance: Varies by project

Possible Award Instruments:

• Procurement contracts

• Grants

• Cooperative agreements

• Other Transaction (OT) agreements for research or prototypes

The Government reserves the right to fund all, some, or none of the submitted proposals and may fund efforts incrementally or with options.

What could I use the funding for?

Funding supports R&D programs aligned to five technical areas:

• BAA 121: Advanced aircraft electrical power systems

• BAA 122: Fuel and lubricant technology

• BAA 123: Aircraft operational energy technology

• BAA 124: Condition-based maintenance, diagnostics, and health monitoring

• BAA 125: Advanced propulsion system technology

Across these areas, funding can be used for:

• Concept feasibility studies

• Modeling and simulation

• Design and engineering

• Prototype development

• Testing and demonstration

• Data analysis and validation

Programs are expected to include structured phases such as design, fabrication, and verification.

Are there any additional benefits I would receive?

Opportunity to transition technology into Navy aircraft systems

• Potential for follow-on funding tied to program success

• Direct alignment with Naval Air Systems Command priorities

• Ability to structure proposals with optional components for incremental funding

Additional benefits are not explicitly specified beyond contract award and potential transition opportunities.

What is the timeline to apply and when would I receive funding?

Submission window: Open continuously until 30 September 2026

• Process:

  • Step 1: Submit White Paper (≤30 pages)

  • Step 2: If invited, submit full technical and cost proposal

• Expected award timing: Fiscal Years 2025–2029

Awards are made on a rolling basis depending on funding availability and program interest.

Where does this funding come from?

• Naval Air Warfare Center Aircraft Division (NAWCAD)

• Air Systems Group, Propulsion & Power Engineering Department

• U.S. Navy / Naval Air Systems Command (NAVAIR)

Who is eligible to apply?

Eligible applicants include:

• Private companies and contractors

• Educational institutions

• Small businesses and disadvantaged businesses

• HBCUs and Minority Institutions

• Veteran-owned and women-owned small businesses

Requirements:

• Must meet Federal Acquisition Regulation (FAR) responsibility standards

• Must be registered in SAM prior to award

• Must have adequate accounting systems (for cost-reimbursable contracts)

Not eligible:

• Foreign governments or foreign entities

What companies and projects are likely to win?

Proposals are evaluated primarily on:

Primary criteria (equal weight):

• Scientific and technical merit

• Relevance and contribution to Navy propulsion, power, and energy objectives

Secondary criteria:

• Team capabilities and past performance

• Cost realism and reasonableness

Winning projects will:

• Align tightly with one of the defined BAA technical areas

• Demonstrate clear military utility and transition potential

• Show strong technical feasibility and ROI

• Be ready for transition (especially for operational energy topics targeting near-term deployment)

Are there any restrictions I should know about?

Foreign entities are not allowed to apply

• Organizational conflicts of interest must be disclosed and mitigated

• SETA contractors cannot simultaneously perform R&D without approval

• Subcontracting plans required for proposals over $700,000 (with small business participation goals)

• Cost-reimbursable contracts require compliant accounting systems

• Government is not obligated to provide requested equipment

Failure to disclose conflicts or meet requirements may result in rejection without evaluation.

How long will it take me to prepare an application?

White Papers are expected to be a few pages up to ~15 pages (max 30 pages)

Full proposals (if invited) require detailed technical and cost volumes

Preparation time is not explicitly specified, but the two-step process is designed to reduce upfront effort by screening via White Papers first.

How can BW&CO help?

BW&CO can:

• Identify the strongest-fit technical area (BAA 121–125)

• Develop a compliant and compelling White Paper

• Position your technology for Navy transition and ROI

• Build a full technical and cost proposal if invited

• Structure optional work packages to maximize award likelihood

How much would BW&CO Charge?

Our full service support is available for a flat fee of $5,000 for the White Paper Submission.

Fractional support is $300 per hour, with most AFRL proposal projects requiring 10-20 hours of expert support from strategy through submission of full proposal.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review solicitation here.

CDMRP: Pancreatic Cancer Research Program (PCARP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Pancreatic Cancer Research Program (PCARP) is anticipated to issue multiple funding opportunities to accelerate impactful research in pancreatic cancer, spanning early detection, supportive care, risk characterization, access to care, metabolic dysregulation, tumor development, biomarkers, and new therapeutics. Investigators should begin planning now—formal Funding Opportunity Announcements (FOAs), deadlines, and application requirements will be posted on Grants.gov once released.

Pre-Applications are due on 7/07 and 9/16,

Full Applications are due on 10/07.

How much funding would I receive?

Funding varies by mechanism:

• Focused Pilot Award: Up to $300,000 total costs over up to 2 years.

• Idea Development Award: Up to $700,000 total costs over up to 3 years(standard) or $950,000 total costs with Partnering PI Option.

• Translational Research Partnership Award: Up to $1.1 million total costs over up to 3 years.

What could I use the funding for?

Funding supports research that directly addresses one or more of the following PCARP Focus Areas:

Scientific & Clinical Focus Areas

• Early detection research

• Identification and characterization of risk

• Supportive care, quality of life, and patient perspectives

• Healthcare access barriers and care delivery challenges

• Metabolic disruptions (including diabetes, cachexia)

• Tumor development from precursor lesions to metastasis

• Biomarkers for response prediction and management strategies

• Novel therapeutic targets and approaches

Each award mechanism may have specific constraints on what types of work it can support (e.g., some do not fund clinical trials or basic research).

Are there any additional benefits I would receive?

• Early insight into programmatic priorities via this pre-announcement.

• Access to eBRAP system for managing pre-applications.

• Email subscription updates when official FOAs are released.

What is the timeline to apply and when would I receive funding?

• Focused Pilot Award

  • 09-16-2026 - (Pre-application - Letter Of Intent)

  • 10-07-2026 - (Application)

• Idea Development Award

  • 07-07-2026 - (Pre-application - Pre-Proposal)

  • 10-07-2026 - (Application)

• Translational Research Partnership Award

  • 07-07-2026 - (Pre-application - Pre-Proposal)

  • 10-07-2026 - (Application)

Where does this funding come from?

PCARP is funded through the FY26 Defense Appropriations Act and managed within the Defense Health Agency Research and Development – Medical Research and Development Command (DHA R&D-MRDC) as part of the Congressionally Directed Medical Research Programs (CDMRP).

Who is eligible to apply?

Eligibility depends on the award mechanism:

• Focused Pilot Award: Investigators at any career level, including postdoctoral and clinical fellows.

• Idea Development Award: Independent investigators at any career stage; early-career investigators may partner with experienced PIs.

• Translational Research Partnership Award: Independent investigators; postdoctoral/clinical fellows are not eligible.

What companies and projects are likely to win?

Projects most competitive for PCARP will:

• Directly address one or more specified focus areas with strong scientific rationale.

• Demonstrate innovation and potential impact on pancreatic cancer outcomes.

• Align with mechanism goals (e.g., pilot studies for early-stage ideas, partnerships for translational work).

• Include appropriate preliminary data when required.

Are there any restrictions I should know about?

• Focused Pilot Award: No basic research, pre-clinical animal studies, or clinical trials.

• Idea Development & Translational Awards: Clinical trials and some animal work may be restricted or defined in FOA; check carefully.

• Pre-proposal or letter of intent submission is required prior to full application for many mechanisms.

How long will it take me to prepare an application?

Time depends on mechanism and data readiness:

• Focused Pilot Award: Plan ~4–8 weeks for a competitive pre-application and research plan.

• Idea Development & Translational Awards: With required preliminary data, plan ~8–16+ weeks to assemble data, collaborators, and a strong proposal.

Start early given the expected complexity of CDMRP applications.

How can BW&CO help?

BW&CO can help you:

• Interpret future FOA requirements and priorities.

• Structure pre-applications/letters of intent for maximum impact.

• Craft narrative, budget justification, and compliance sections.

• Align scientific aims with program focus areas to increase competitiveness.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Lupus Research Program (LRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The CDMRP’s FY26 Lupus Research Program (LRP) pre-announcement signals anticipated funding opportunities supporting innovative, high-impact lupus research aimed at understanding, preventing, diagnosing, and treating lupus, as well as improving the quality of life for individuals living with lupus.

Pre-Applications are due on 7/29.

Full-Applications are due on 8/19.

How much funding would I receive?

The pre-announcement outlines multiple award mechanisms with specified maximum total costs:

• Idea Award – up to $300,000 (2 years)

• Impact Award – up to $1,000,000 (4 years)

• Transformative Vision Development Award – up to $250,000 (2 years)

• Transformative Vision Award – up to $2,000,000 (4 years)

What could I use the funding for?

Funding must support research aligned with one or more LRP focus areas:

Biological & Clinical Research

• Mechanisms of lupus disease and pathobiology

• Genetic, epigenetic, and gene–environment interaction studies

• Disease heterogeneity, presentations, and outcomes
  Applies to Idea & Impact Awards

Quality of Life & Intervention Studies

• Addressing social determinants of health

• Nutrition, symptom control, comparative effectiveness

• Outcomes research and patient-reported outcomes
  Applies to Impact, Transformative Vision Development, and Transformative Vision Awards

Innovative Health Care Delivery Models

• Models improving lupus outcomes
  Applies to Impact, Transformative Vision Development, and Transformative Vision Awards

Are there any additional benefits I would receive?

• Mechanism clarity ahead of FOAs allows early planning.

• Subscribe to email updates through eBRAP for timely notifications when FOAs are released.

• Being positioned early can improve competitiveness.

What is the timeline to apply and when would I receive funding?

Pre-Applications are due on 7/29.

Full-Applications are due on 8/19.

Where does this funding come from?

Funding is provided through the FY26 Defense Appropriations Act appropriated to the Congressionally Directed Medical Research Programs (CDMRP) and managed by the Defense Health Agency Research & Development and Medical Research and Development Command (DHA R&D-MRDC).

Who is eligible to apply?

Eligibility is defined by mechanism:

• Idea Award: Investigators at or above postdoctoral level.

• Impact & Transformative Awards: Investigators at or above Assistant Professor (or equivalent).

• Team Requirements: Transformative mechanisms must include at least one lupus consumer advocate as part of the research team.

What companies and projects are likely to win?

Projects that:

• Align tightly with the specified focus areas.

• Demonstrate high innovation and impact potential.

• Involve strong preliminary data (as required for Transformative Vision Award).

• Include meaningful involvement of lupus consumer advocates (for transformative mechanisms).

Are there any restrictions I should know about?

• This pre-announcement is not a funding commitment; only the FOAs establish requirements and obligations.

• Applications cannot support clinical trials in Idea or Impact Awards; Transformative Vision Awards may support clinical trials but not animal studies.

• Transformative Vision Development Awards cannot support clinical trials or animal studies.

How long will it take me to prepare an application?

Preparation time depends on mechanism and complexity, but begin planning now — especially for pilot data and consumer engagement for transformative mechanisms. Historically, competitive CDMRP applications often require several weeks to months of focused preparation.

How can BW&CO help?

BW&CO can:

• Develop alignment narratives tied to LRP focus areas.

• Assist with preliminary data framing and research strategy articulation.

• Craft strong consumer advocacy integration plans.

• Ensure conformity with CDMRP review criteria once FOAs are released.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.